{
  "pmcid": "PMC12684531",
  "source": "PMC",
  "download_date": "2025-12-09T16:37:14.459783",
  "metadata": {
    "journal_title": "Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease",
    "journal_nlm_ta": "J Am Heart Assoc",
    "journal_iso_abbrev": "J Am Heart Assoc",
    "journal": "Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease",
    "pmcid": "PMC12684531",
    "pmid": "41025452",
    "doi": "10.1161/JAHA.125.043486",
    "title": "Acute Valve Syndrome Before Aortic Valve Replacement: Impact on Clinical Outcomes, Health Care Costs, and Resource Use",
    "year": "2025",
    "month": "9",
    "day": "30",
    "pub_date": {
      "year": "2025",
      "month": "9",
      "day": "30"
    },
    "authors": [
      "Généreux Philippe",
      "Giustino Gennaro",
      "Lindman Brian R.",
      "Pibarot Philippe",
      "Baron Suzanne J.",
      "Asselin Chantal",
      "Dratch Alissa",
      "Murphy Shannon M. E.",
      "Chikermane Soumya",
      "Thourani Vinod H.",
      "Koulogiannis Kostantinos P.",
      "Schwartz Allan",
      "Leon Martin B.",
      "Pellikka Patricia P.",
      "Gillam Linda D."
    ],
    "abstract": "Background A classification system describing clinical presentation before aortic valve replacement (AVR) has recently been proposed (stable valve syndrome [SVS]), mildly symptomatic (progressive valve syndrome), or with acute and severe signs and symptoms (acute valve syndrome [AVS]). We aimed to evaluate the clinical impact, health care costs, and resource use associated with the mode of clinical presentation at the time of AVR among patients presenting with aortic stenosis. Methods Using the Market Clarity database (2017–2023), patients >18 years old with aortic stenosis and undergoing AVR (transcatheter or surgical) were included. Patients were categorized as SVS, progressive valve syndrome, or AVS based on their clinical presentation during the 1 year before AVR. All‐cause death, heart failure hospitalization, total health care costs (index hospitalization plus 1‐year follow‐up), and resource use were compared across clinical presentation groups using adjusted regression models. Results Of the 24 075 patients undergoing AVR for aortic stenosis, 270 (1.1%) had SVS, 10 195 (42.3%) progressive valve syndrome, and 13 610 (56.5%) AVS. Compared with SVS, AVS presentation was associated with increased risk of 1‐year death (adjusted hazard ratio [aHR], 2.93 [95% CI, 1.1–7.8];  P =0.03) and heart failure hospitalization (aHR, 4.15 [95% CI, 1.6–11.1];  P <0.01) after AVR. The total costs of AVR and 1‐year follow‐up were significantly higher in both the progressive valve syndrome (difference $27 410 [$13 507–$41 314]) and AVS groups (difference $36 267 [$22 302–$50 232]) compared with patients with SVS. Conclusions AVS was frequent among patients undergoing AVR and was associated with increase in death, heart failure hospitalization, health care costs, and resource use 1 year after AVR, and SVS presentation was associated with the best clinical and economic outcomes.",
    "keywords": [
      "acute valve syndrome",
      "aortic stenosis",
      "aortic valve replacement",
      "asymptomatic",
      "health care cost",
      "Aortic Valve Replacement/Transcather Aortic Valve Implantation",
      "Cardiovascular Surgery"
    ]
  },
  "xml": "<?xml version=\"1.0\"  ?><!DOCTYPE pmc-articleset PUBLIC \"-//NLM//DTD ARTICLE SET 2.0//EN\" \"https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd\"><pmc-articleset><article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" id=\"jah311439\" xml:lang=\"en\" article-type=\"research-article\" dtd-version=\"1.4\"><processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">J Am Heart Assoc</journal-id><journal-id journal-id-type=\"iso-abbrev\">J Am Heart Assoc</journal-id><journal-id journal-id-type=\"pmc-domain-id\">1888</journal-id><journal-id journal-id-type=\"pmc-domain\">jaha</journal-id><journal-id journal-id-type=\"publisher-id\">JAH3</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type=\"epub\">2047-9980</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmcid\">PMC12684531</article-id><article-id pub-id-type=\"pmcid-ver\">PMC12684531.1</article-id><article-id pub-id-type=\"pmcaid\">12684531</article-id><article-id pub-id-type=\"pmcaiid\">12684531</article-id><article-id pub-id-type=\"pmid\">41025452</article-id><article-id pub-id-type=\"doi\">10.1161/JAHA.125.043486</article-id><article-id pub-id-type=\"publisher-id\">JAH311439</article-id><article-id pub-id-type=\"other\">JAHA/2025/043486-T</article-id><article-version article-version-type=\"pmc-version\">1</article-version><article-categories><subj-group subj-group-type=\"overline\"><subject>Original Research</subject></subj-group><subj-group subj-group-type=\"heading\"><subject>Original Research</subject><subj-group subj-group-type=\"heading\"><subject>Valvular Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Acute Valve Syndrome Before Aortic Valve Replacement: Impact on Clinical Outcomes, Health Care Costs, and Resource Use</article-title><alt-title alt-title-type=\"right-running-head\">Acute Valve Syndrome in Aortic Stenosis Before <styled-content style=\"fixed-case\" toggle=\"no\">AVR</styled-content></alt-title><alt-title alt-title-type=\"left-running-head\">G&#233;n&#233;reux et&#160;al</alt-title></title-group><contrib-group><contrib id=\"jah311439-cr-0001\" contrib-type=\"author\" corresp=\"yes\"><name name-style=\"western\"><surname>G&#233;n&#233;reux</surname><given-names initials=\"P\">Philippe</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-5507-3712</contrib-id><xref rid=\"jah311439-aff-0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref><address><email>philippe.genereux@atlantichealth.org</email></address></contrib><contrib id=\"jah311439-cr-0002\" contrib-type=\"author\"><name name-style=\"western\"><surname>Giustino</surname><given-names initials=\"G\">Gennaro</given-names></name><degrees>MD</degrees><xref rid=\"jah311439-aff-0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0003\" contrib-type=\"author\"><name name-style=\"western\"><surname>Lindman</surname><given-names initials=\"BR\">Brian R.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-6879-5343</contrib-id><xref rid=\"jah311439-aff-0002\" ref-type=\"aff\">\n<sup>2</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0004\" contrib-type=\"author\"><name name-style=\"western\"><surname>Pibarot</surname><given-names initials=\"P\">Philippe</given-names></name><degrees>DVM, PhD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-3607-279X</contrib-id><xref rid=\"jah311439-aff-0003\" ref-type=\"aff\">\n<sup>3</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0005\" contrib-type=\"author\"><name name-style=\"western\"><surname>Baron</surname><given-names initials=\"SJ\">Suzanne J.</given-names></name><degrees>MD, MSc</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-8319-5637</contrib-id><xref rid=\"jah311439-aff-0004\" ref-type=\"aff\">\n<sup>4</sup>\n</xref><xref rid=\"jah311439-aff-0005\" ref-type=\"aff\">\n<sup>5</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0006\" contrib-type=\"author\"><name name-style=\"western\"><surname>Asselin</surname><given-names initials=\"C\">Chantal</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0003-2088-2752</contrib-id><xref rid=\"jah311439-aff-0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0007\" contrib-type=\"author\"><name name-style=\"western\"><surname>Dratch</surname><given-names initials=\"A\">Alissa</given-names></name><degrees>MPH</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-2315-979X</contrib-id><xref rid=\"jah311439-aff-0006\" ref-type=\"aff\">\n<sup>6</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0008\" contrib-type=\"author\"><name name-style=\"western\"><surname>Murphy</surname><given-names initials=\"SME\">Shannon M. E.</given-names></name><degrees>MA</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0001-7429-9365</contrib-id><xref rid=\"jah311439-aff-0006\" ref-type=\"aff\">\n<sup>6</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0009\" contrib-type=\"author\"><name name-style=\"western\"><surname>Chikermane</surname><given-names initials=\"S\">Soumya</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0001-5335-3430</contrib-id><xref rid=\"jah311439-aff-0006\" ref-type=\"aff\">\n<sup>6</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0010\" contrib-type=\"author\"><name name-style=\"western\"><surname>Thourani</surname><given-names initials=\"VH\">Vinod H.</given-names></name><degrees>MD</degrees><xref rid=\"jah311439-aff-0007\" ref-type=\"aff\">\n<sup>7</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0011\" contrib-type=\"author\"><name name-style=\"western\"><surname>Koulogiannis</surname><given-names initials=\"KP\">Kostantinos P.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-5889-0865</contrib-id><xref rid=\"jah311439-aff-0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0012\" contrib-type=\"author\"><name name-style=\"western\"><surname>Schwartz</surname><given-names initials=\"A\">Allan</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0001-5576-2385</contrib-id><xref rid=\"jah311439-aff-0008\" ref-type=\"aff\">\n<sup>8</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0013\" contrib-type=\"author\"><name name-style=\"western\"><surname>Leon</surname><given-names initials=\"MB\">Martin B.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-2002-7492</contrib-id><xref rid=\"jah311439-aff-0008\" ref-type=\"aff\">\n<sup>8</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0014\" contrib-type=\"author\"><name name-style=\"western\"><surname>Pellikka</surname><given-names initials=\"PP\">Patricia P.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0001-6800-3521</contrib-id><xref rid=\"jah311439-aff-0009\" ref-type=\"aff\">\n<sup>9</sup>\n</xref></contrib><contrib id=\"jah311439-cr-0015\" contrib-type=\"author\"><name name-style=\"western\"><surname>Gillam</surname><given-names initials=\"LD\">Linda D.</given-names></name><degrees>MD, MPH</degrees><contrib-id contrib-id-type=\"orcid\" authenticated=\"false\">https://orcid.org/0000-0002-1716-7574</contrib-id><xref rid=\"jah311439-aff-0001\" ref-type=\"aff\">\n<sup>1</sup>\n</xref></contrib></contrib-group><aff id=\"jah311439-aff-0001\">\n<label>\n<sup>1</sup>\n</label>\n<institution>Gagnon Cardiovascular Institute, Morristown Medical Center</institution>\n<city>Morristown</city>\n<named-content content-type=\"country-part\">NJ</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0002\">\n<label>\n<sup>2</sup>\n</label>\n<institution>Vanderbilt University Medical Center</institution>\n<city>Nashville</city>\n<named-content content-type=\"country-part\">TN</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0003\">\n<label>\n<sup>3</sup>\n</label>\n<institution>Laval University</institution>\n<named-content content-type=\"street\">Quebec City</named-content>\n<city>Quebec</city>\n<country country=\"CA\">Canada</country>\n</aff><aff id=\"jah311439-aff-0004\">\n<label>\n<sup>4</sup>\n</label>\n<institution>Massachusetts General Hospital</institution>\n<city>Boston</city>\n<named-content content-type=\"country-part\">MA</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0005\">\n<label>\n<sup>5</sup>\n</label>\n<institution>Baim Institute of Clinical Research</institution>\n<city>Boston</city>\n<named-content content-type=\"country-part\">MA</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0006\">\n<label>\n<sup>6</sup>\n</label>\n<institution>Edwards Lifesciences</institution>\n<city>Irvine</city>\n<named-content content-type=\"country-part\">CA</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0007\">\n<label>\n<sup>7</sup>\n</label>\n<institution>Piedmont Heart and Vascular Institute</institution>\n<city>Atlanta</city>\n<named-content content-type=\"country-part\">GA</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0008\">\n<label>\n<sup>8</sup>\n</label>\n<institution>NewYork&#8208;Presbyterian Hospital/Columbia University Irving Medical Center</institution>\n<city>New York</city>\n<named-content content-type=\"country-part\">NY</named-content>\n<country country=\"US\">USA</country>\n</aff><aff id=\"jah311439-aff-0009\">\n<label>\n<sup>9</sup>\n</label>\n<institution>Mayo Clinic</institution>\n<city>Rochester</city>\n<named-content content-type=\"country-part\">MN</named-content>\n<country country=\"US\">USA</country>\n</aff><author-notes><corresp id=\"correspondenceTo\"><label>*</label>\nCorrespondence to: Philippe G&#233;n&#233;reux, MD, Gagnon Cardiovascular Institute, Morristown Medical Center, 100 Madison Avenue, Morristown, NJ 07960. Email: <email>philippe.genereux@atlantichealth.org</email><break/></corresp></author-notes><pub-date pub-type=\"epub\"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type=\"collection\"><day>07</day><month>10</month><year>2025</year></pub-date><volume>14</volume><issue seq=\"610\">19</issue><issue-id pub-id-type=\"pmc-issue-id\">502073</issue-id><issue-id pub-id-type=\"doi\">10.1002/jah3.v14.19</issue-id><elocation-id>e043486</elocation-id><history><date date-type=\"received\"><day>05</day><month>5</month><year>2025</year></date><date date-type=\"accepted\"><day>05</day><month>8</month><year>2025</year></date></history><pub-history><event event-type=\"pmc-release\"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type=\"pmc-live\"><date><day>09</day><month>12</month><year>2025</year></date></event><event event-type=\"pmc-last-change\"><date iso-8601-date=\"2025-12-09 10:25:13.050\"><day>09</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type=\"article-copyright\">&#169; 2025 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref specific-use=\"textmining\" content-type=\"ccbyncndlicense\">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by-nc-nd/4.0/\">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"pmc-pdf\" xlink:href=\"JAH3-14-e043486.pdf\"/><self-uri xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"pdf\" xlink:href=\"file:JAH3-14-e043486.pdf\"/><related-article xmlns:xlink=\"http://www.w3.org/1999/xlink\" related-article-type=\"companion\" xml:lang=\"en\" xlink:title=\"editorial\" journal-id=\"J Am Heart Assoc\" journal-id-type=\"nlm-ta\" ext-link-type=\"pmc\" xlink:href=\"PMC12684557\"><article-title>Impact of Acute Valve Syndrome on Outcomes of Aortic Valve Replacement for&#160;Aortic Stenosis</article-title><volume>14</volume><issue seq=\"620\">19</issue><date><day>30</day><month>9</month><year>2025</year></date><elocation-id>e046270</elocation-id><source>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</source><pub-id pub-id-type=\"doi\">10.1161/JAHA.125.046270</pub-id><pub-id pub-id-type=\"pmcid\">PMC12684557</pub-id><pub-id pub-id-type=\"pmid\">41025497</pub-id></related-article><abstract><sec id=\"jah311439-sec-0001\"><title>Background</title><p>A classification system describing clinical presentation before aortic valve replacement (AVR) has recently been proposed (stable valve syndrome [SVS]), mildly symptomatic (progressive valve syndrome), or with acute and severe signs and symptoms (acute valve syndrome [AVS]). We aimed to evaluate the clinical impact, health care costs, and resource use associated with the mode of clinical presentation at the time of AVR among patients presenting with aortic stenosis.</p></sec><sec id=\"jah311439-sec-0002\"><title>Methods</title><p>Using the Market Clarity database (2017&#8211;2023), patients &gt;18&#8201;years old with aortic stenosis and undergoing AVR (transcatheter or surgical) were included. Patients were categorized as SVS, progressive valve syndrome, or AVS based on their clinical presentation during the 1 year before AVR. All&#8208;cause death, heart failure hospitalization, total health care costs (index hospitalization plus 1&#8208;year follow&#8208;up), and resource use were compared across clinical presentation groups using adjusted regression models.</p></sec><sec id=\"jah311439-sec-0003\"><title>Results</title><p>Of the 24&#8201;075 patients undergoing AVR for aortic stenosis, 270 (1.1%) had SVS, 10 195 (42.3%) progressive valve syndrome, and 13&#8201;610 (56.5%) AVS. Compared with SVS, AVS presentation was associated with increased risk of 1&#8208;year death (adjusted hazard ratio [aHR], 2.93 [95% CI, 1.1&#8211;7.8]; <italic toggle=\"no\">P</italic>=0.03) and heart failure hospitalization (aHR, 4.15 [95% CI, 1.6&#8211;11.1]; <italic toggle=\"no\">P</italic>&lt;0.01) after AVR. The total costs of AVR and 1&#8208;year follow&#8208;up were significantly higher in both the progressive valve syndrome (difference $27&#8201;410 [$13&#8201;507&#8211;$41&#8201;314]) and AVS groups (difference $36&#8201;267 [$22&#8201;302&#8211;$50&#8201;232]) compared with patients with SVS.</p></sec><sec id=\"jah311439-sec-0004\"><title>Conclusions</title><p>AVS was frequent among patients undergoing AVR and was associated with increase in death, heart failure hospitalization, health care costs, and resource use 1 year after AVR, and SVS presentation was associated with the best clinical and economic outcomes.</p></sec></abstract><abstract abstract-type=\"graphical\"><p>\n<boxed-text position=\"anchor\" content-type=\"graphic\" id=\"jah311439-blkfxd-0001\" orientation=\"portrait\"><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" position=\"anchor\" id=\"jats-graphic-1\" orientation=\"portrait\" xlink:href=\"JAH3-14-e043486-g002.jpg\"/></boxed-text>\n</p></abstract><kwd-group kwd-group-type=\"author-generated\"><kwd id=\"jah311439-kwd-0001\">acute valve syndrome</kwd><kwd id=\"jah311439-kwd-0002\">aortic stenosis</kwd><kwd id=\"jah311439-kwd-0003\">aortic valve replacement</kwd><kwd id=\"jah311439-kwd-0004\">asymptomatic</kwd><kwd id=\"jah311439-kwd-0005\">health care cost</kwd></kwd-group><kwd-group kwd-group-type=\"subject-categories\"><title>Subject Categories</title><kwd>Aortic Valve Replacement/Transcather Aortic Valve Implantation</kwd><kwd>Cardiovascular Surgery</kwd></kwd-group><counts><fig-count count=\"4\"/><table-count count=\"2\"/><page-count count=\"10\"/><word-count count=\"5600\"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>07 October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:21.11.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id=\"jah311439-ntgp-0001\"><fn id=\"jah311439-note-0001\"><p>This article was sent to Michel Pompeu S&#225;, MD, MSc, MHBA, PhD, FACC, FAHA, Assistant Editor, for review by expert referees, editorial decision, and final disposition.</p><p>Part of this work was presented as an oral presentation at EuroPCR, May 20&#8211;23, 2025, in Paris, France.</p></fn><fn id=\"jah311439-note-0002\"><p>Supplemental Material is available at <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.043486\" ext-link-type=\"uri\">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.043486</ext-link>\n</p></fn><fn id=\"jah311439-note-0003\"><p>For Disclosures, see page 10.</p></fn></fn-group></notes></front><body id=\"jah311439-body-0001\"><def-list list-content=\"abbreviations\" id=\"jah311439-dl-0001\"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id=\"jah311439-li-0001\">AS</term><def id=\"jah311439-li-0002\"><p>aortic stenosis</p></def></def-item><def-item><term id=\"jah311439-li-0003\">AVR</term><def id=\"jah311439-li-0004\"><p>aortic valve replacement</p></def></def-item><def-item><term id=\"jah311439-li-0005\">AVS</term><def id=\"jah311439-li-0006\"><p>acute valve syndrome</p></def></def-item><def-item><term id=\"jah311439-li-0007\">HFH</term><def id=\"jah311439-li-0008\"><p>heart failure hospitalization</p></def></def-item><def-item><term id=\"jah311439-li-0009\">NYHA</term><def id=\"jah311439-li-0010\"><p>New York Heart Association</p></def></def-item><def-item><term id=\"jah311439-li-0011\">PVS</term><def id=\"jah311439-li-0012\"><p>progressive valve syndrome</p></def></def-item><def-item><term id=\"jah311439-li-0013\">SAVR</term><def id=\"jah311439-li-0014\"><p>surgical aortic valve replacement</p></def></def-item><def-item><term id=\"jah311439-li-0015\">SVS</term><def id=\"jah311439-li-0016\"><p>stable valve syndrome</p></def></def-item><def-item><term id=\"jah311439-li-0017\">TAVR</term><def id=\"jah311439-li-0018\"><p>transcatheter aortic valve replacement</p></def></def-item></def-list><p>\n<boxed-text position=\"anchor\" content-type=\"box\" id=\"jah311439-blkfxd-0002\" orientation=\"portrait\"><caption><title>Clinical Perspective</title></caption><sec id=\"jah311439-sec-0007\"><title>What Is New?</title><p>\n<list list-type=\"bullet\" id=\"jah311439-list-0001\"><list-item id=\"jah311439-li-0019\"><p>Among patients with aortic stenosis undergoing aortic valve replacement (AVR), presentation with acute and advanced symptoms (acute valve syndrome) is frequent; clinical presentation with acute valve syndrome before AVR is associated with increased mortality and heart failure hospitalization after AVR.</p></list-item><list-item id=\"jah311439-li-0020\"><p>Asymptomatic patients (stable valve syndrome) undergoing AVR had the most favorable outcomes after AVR; presentation with acute valve syndrome and progressive valve syndrome is associated with increased health care cost and resource use compared with patients presenting with stable valve syndrome.</p></list-item></list>\n</p></sec><sec id=\"jah311439-sec-0008\"><title>What Are the Clinical Implications?</title><p>\n<list list-type=\"bullet\" id=\"jah311439-list-0002\"><list-item id=\"jah311439-li-0021\"><p>Based on the worst clinical and economical outcomes associated with acute valve syndrome and progressive valve syndrome presentation, performing AVR when patients with aortic stenosis are stable and with no symptoms (stable valve syndrome) should be the preferred strategy.</p></list-item></list>\n</p></sec></boxed-text>\n</p><p>Aortic stenosis (AS) is a progressive disease characterized by periods of latency and variable evolution. Although some patients have a slow and indolent progression, others present with aggressive disease, with dramatic signs and symptoms. Recently, we proposed a novel classification system describing patients' clinical presentation before aortic valve replacement (AVR).<xref rid=\"jah311439-bib-0001\" ref-type=\"bibr\">\n<sup>1</sup>\n</xref>, <xref rid=\"jah311439-bib-0002\" ref-type=\"bibr\">\n<sup>2</sup>\n</xref> Patients were categorized into 3 groups based on their clinical presentation before AVR: asymptomatic or stable valve syndrome (SVS); mildly symptomatic or progressive valve syndrome (PVS), such as New York Heart Association (NYHA) class II;&#160;or acute valve syndrome (AVS), such as NYHA class III&#8211;IV, heart failure hospitalization (HFH), syncope, or cardiac arrest.</p><p>Among a real&#8208;world population of &gt;17&#8201;000 patients undergoing AVR for AS, AVS presentation was associated with a 3&#8208;fold increase in mortality and a 4&#8208;fold increase in risk of HFH 2&#8201;years after AVR compared with patients presenting with no symptoms<xref rid=\"jah311439-bib-0001\" ref-type=\"bibr\">\n<sup>1</sup>\n</xref>; however, those findings have not been confirmed by further research, and the economic impact associated with the mode of clinical presentation before AVR has never been reported. Therefore, using a different patient population, we aimed to (1) externally validate the clinical impact of this new clinical presentation classification and (2) evaluate the health care costs and resources use associated with the mode of clinical presentation before AVR.</p><sec sec-type=\"methods\" id=\"jah311439-sec-0009\"><title>METHODS</title><sec id=\"jah311439-sec-0010\"><title>Objectives</title><p>The primary objective of the current study was to assess the clinical impact of the mode of clinical presentation on death and HFH after AVR. We also aimed to quantify differences in total health care costs (index AVR hospitalization plus 1&#8208;year follow&#8208;up) across patients presenting with SVS, PVS, and AVS before AVR. Secondary objectives included comparing patterns of resource use, specifically hospital length of stay, all&#8208;cause hospitalizations, and HFH. We hypothesized that AVS will be associated with worse clinical outcomes compared with SVS, and that health care costs and resource use would demonstrate a stepwise increase with more advanced clinical presentations.</p></sec><sec id=\"jah311439-sec-0011\"><title>Data Source</title><p>This research made use of Optum's deidentified Market Clarity data, an extensive health care database that integrates data from both Optum&#8208;affiliated and nonaffiliated providers in the United States. The database is derived from longitudinal inpatient and outpatient electronic health record records (EHRs) for 81 million US patients across all 50 states who receive care from 1 of the participating provider organizations. Additionally, a subset of these patients has linked medical and pharmacy claims data. The combined EHR and claims data offer comprehensive information on patient demographics, medical details (such as laboratory test results), procedures, outcomes, and medications, as well as provider information and notes. Natural language processing (NLP) is applied to unstructured clinical notes, enabling extraction of detailed clinical information, including diagnosis codes, symptoms, biomarkers, and laboratory values. The Optum NLP system was developed using vocabulary from the Unified Medical Language System that includes multiple medical dictionaries such as the <italic toggle=\"yes\">Logical Observation Identifiers Names and Codes</italic>, the <italic toggle=\"yes\">Systemized Nomenclature of Medicine&#8208;Clinical Terms</italic>, and <italic toggle=\"yes\">RxNorm</italic>, a listing of generic and branded drugs (among others). NLP concepts are identified and created based on broad topics such as medications, signs, disease and symptoms, measurements, and observations. The data are harvested from the notes fields within the electronic medical records provided to Optum from &gt;50 large health care systems throughout the United States. The data used for development of each NLP concept are deidentified, and accuracy is verified through a series of quality assurance steps before release for use. Each NLP concept included in the data is associated with a unique subject record and a date of observation.</p><p>For cardiac patients, the Market Clarity database captures detailed clinical parameters including echocardiographic findings, relevant biomarkers, and comprehensive documentation of cardiovascular symptoms and complications. The integrated nature of the data set allows tracking of both clinical outcomes and health care resource use. Coding details are provided in Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S1</xref>.</p><p>All data were deidentified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a deidentified database, the research was exempt from institutional review board review under 45 CFR 46.101(b) (4). No informed consent were required. The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec id=\"jah311439-sec-0012\"><title>Study Population</title><p>Adult patients (&#8805;18&#8201;years old) who underwent either transcatheter AVR (TAVR) or surgical AVR (SAVR) for AS between 2017 and 2023 Quater 1&#160;were identified from the Market Clarity database. Eligible patients were required to have continuous medical claims coverage for 1 year before AVR through discharge, and to be enrolled in an integrated delivery network with EHR, claims, and physician records available. Patients with documented moderate or severe aortic regurgitation were excluded.</p><p>Based on the clinical presentation classification previously published by G&#233;n&#233;reux and colleagues,<xref rid=\"jah311439-bib-0001\" ref-type=\"bibr\">\n<sup>1</sup>\n</xref> patients were categorized into 3 groups based on their clinical presentation before AVR: (1) SVS, described as patients with no documented signs or symptoms of AS; (2) PVS, described as patients with NYHA class II symptoms (dyspnea, fatigue, dizziness, angina) or diagnosed diastolic heart failure, edema, or mildly elevated natriuretic peptides (B&#8208;type natriuretic peptide 100&#8211;400 pg/mL or NT&#8208;proBNP [N&#8208;terminal pro&#8208;B&#8208;type natriuretic peptide] 1000&#8211;1500 pg/mL); or (3) AVS, described as NYHA class III&#8211;IV symptoms, HFH, new drop in left ventricular ejection fraction &lt;50%, admission with systolic heart failure, significantly elevated natriuretic peptides (B&#8208;type natriuretic peptide &#8805;400 pg/mL or NT&#8208;proBNP &#8805;1500 pg/mL), new&#8208;onset atrial fibrillation, syncope, cardiogenic shock, or cardiac arrest. Coding details are provided in Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S1</xref>.</p></sec><sec id=\"jah311439-sec-0013\"><title>Variables of Interest</title><p>The primary outcomes were all&#8208;cause death, HFH, stroke/transient ischemic attack hospitalization, the composite end point of death or HFH, and total costs (index AVR plus 1&#8208;year follow&#8208;up, annualized), with secondary analyses examining index hospitalization and follow&#8208;up costs separately. Additional 1&#8208;year follow&#8208;up outcomes of interest included total hospitalizations, HFH, total inpatient days, and heart failure inpatient days. The main independent variable was AS presentation category (SVS, PVS, or AVS) as defined previously.<xref rid=\"jah311439-bib-0001\" ref-type=\"bibr\">\n<sup>1</sup>\n</xref> Covariates included patient demographics (age, sex, White race, geographic census region, insurance type), procedure type (TAVR versus SAVR), key clinical conditions within the 1&#8208;year baseline period (chronic kidney disease on dialysis, chronic obstructive pulmonary disease with oxygen dependence, prior percutaneous coronary intervention, prior coronary artery bypass grafting), comorbidity measure (Elixhauser comorbidity score), and a measure of frailty (Hospital Frailty Risk Score).</p><p>The Quan Elixhauser comorbidity score is a validated method for measuring patient comorbidity based on 31 conditions identified from <italic toggle=\"yes\">International Classification of Diseases</italic> (<italic toggle=\"yes\">ICD</italic>) 9th and 10th revision&#160;diagnosis codes.<xref rid=\"jah311439-bib-0003\" ref-type=\"bibr\">\n<sup>3</sup>\n</xref> The score ranges from 0 to 31, with higher scores indicating greater comorbidity burden. The Hospital Frailty Risk Score is a validated score derived from <italic toggle=\"yes\">ICD 10th</italic> revision diagnosis codes that identifies frail patients at increased risk of adverse events.<xref rid=\"jah311439-bib-0004\" ref-type=\"bibr\">\n<sup>4</sup>\n</xref> The score typically ranges from 0 to &gt;20, with scores &gt;5 indicating intermediate risk and scores &gt;15 indicating high risk. Baseline health care costs and use 1 year before the AVR procedure included total health care costs, inpatient days, and all&#8208;cause hospitalizations.</p></sec><sec id=\"jah311439-sec-0014\"><title>Statistical Analysis</title><p>We performed 4 key time&#8208;to&#8208;event analyses to evaluate clinical outcomes by severity group: time to death, time to first HFH, time to the composite end point of death or HFH, and time to first stroke/transient ischemic attack hospitalization. For outcomes without competing risks (death and composite end point), we generated unadjusted Kaplan&#8208;Meier curves to obtain outcome rates through 1 year and used covariate&#8208;adjusted Cox proportional hazards models to test for differences by clinical presentation. The proportional hazards assumption was assessed using a visual inspection of the Kaplan&#8208;Meier curves and the Schoenfeld residuals test, and there was no meaningful violation of the proportional hazard assumption. When analyzing outcomes with a competing risk of death (HFH and stroke/transient ischemic attack), we used competing risks methodology, using unadjusted cumulative incidence function plots and covariate&#8208;adjusted Fine&#8208;Gray regression modeling of subdistribution hazards. Adjusted hazard ratios are displayed on the Kaplan&#8208;Meier plots, and adjusted subdistribution hazard ratios are displayed on the cumulative incidence plots.</p><p>For cost and use outcomes, we used generalized linear models to analyze our primary outcome of total costs and secondary outcomes including costs and use during and after the index AVR hospitalization. Each model was run twice: (1) to estimate adjusted mean outcomes by clinical presentation and to calculate the adjusted risk of AVS and PVS compared with SVS (with clinical presentation defined as a categorical variable), and (2) to test if there was a significant linear trend in the outcome across SVS, PVS, and AVS (with clinical presentation defined as a continuous variable and the result reported as <italic toggle=\"yes\">P</italic>\n<sub>trend</sub>). All adjusted models included covariate adjustment for demographic factors (age, sex, White race), geographic region, insurance type, procedure type (TAVR versus SAVR), clinical risk scores (Elixhauser comorbidity score and frailty score), and key comorbidities, including chronic kidney disease on dialysis, chronic obstructive pulmonary disease on oxygen, prior percutaneous coronary intervention, and prior coronary artery bypass grafting. Outcome modeling was based on a &#947; distribution (costs) or a negative binomial distribution (admission counts and days with overdispersion) and log links.</p><p>To reduce the impact of extreme values, we trimmed all cost and use outcomes at the 99th percentile within each severity group. In our presentation of results, we report categorical variables as percentage and continuous variables as mean&#177;SD. Statistical significance was defined as <italic toggle=\"yes\">P</italic>&lt;0.05 for all analyses.</p><p>Two post hoc analyses were conducted and reported in Tables&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S2</xref> and <xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S3</xref>. The first was to assess the association between clinical presentation at AVR and the risk of HFH within 30&#8201;days (Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S2</xref>). The odds ratios were calculated using a logistic regression model that incorporated Firth's bias reduction method (penalized maximum likelihood correction). This method was used to produce reasonable estimates, because the asymptomatic group had 0 events. Second, we conducted a stratified analysis of AVR hospitalization cost and AVR length of stay by AVR type to see if the results were observed for both TAVR and SAVR (Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S3</xref>).</p></sec></sec><sec sec-type=\"results\" id=\"jah311439-sec-0015\"><title>RESULTS</title><sec id=\"jah311439-sec-0016\"><title>Study Population</title><p>From 2017 to 2023 Quater 1 in the Market Clarity database, 110&#8201;867 patients who underwent AVR procedures for AS were considered for analysis. After systematically excluding patients who were not a part of the Integrated Delivery Network (n=11&#8201;869), lacking complete EHR and claims data (n=7563), missing physician notes (n=12&#8201;319), not continuously enrolled during the baseline year (n=50&#8201;269), or who had a physician note stating presence or absence of moderate or severe aortic regurgitation (n=1973), we then limited the cohort to those &#8805;18&#8201;years old at AVR (n=26&#8201;880). Next, we categorized these patients into SVS, PVS, or AVS based on clinical presentation at AVR; we were unable to categorize 2805 patients due to lack of necessary data. Thus, our final cohort included 24&#8201;075 eligible patients (Figure&#160;<xref rid=\"jah311439-fig-0001\" ref-type=\"fig\">1</xref>). Of those, 270 (1.1%) presented with SVS before AVR, 10 195 (42.3%) with PVS, and 13&#8201;610 (56.5%) with AVS. TAVR was performed in 13&#8201;483 (56%) patients, and SAVR was performed in 10&#8201;465 (44%) patients. In general, patients presenting with AVS before AVR were older and had more concomitant disease and comorbidities compared with patients with PVS or SVS (Table&#160;<xref rid=\"jah311439-tbl-0001\" ref-type=\"table\">1</xref>). Women made up 38.9% of the studied population.</p><fig position=\"float\" fig-type=\"Figure\" id=\"jah311439-fig-0001\" orientation=\"portrait\"><label>Figure 1</label><caption><title>Study patient attrition diagram.</title><p>AR indicates aortic regurgitation; AV, aortic valve; AVR, aortic valve replacement; AVS, acute valve syndrome; EHR, electronic health record; and PVS, progressive valve syndrome.</p></caption><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" position=\"anchor\" id=\"jats-graphic-3\" orientation=\"portrait\" xlink:href=\"JAH3-14-e043486-g004.jpg\"/></fig><table-wrap position=\"float\" id=\"jah311439-tbl-0001\" content-type=\"Table\" orientation=\"portrait\"><label>Table 1</label><caption><p>Baseline Characteristics</p></caption><table frame=\"hsides\" rules=\"groups\"><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><thead><tr style=\"border-bottom:solid 1px #000000\"><th align=\"left\" rowspan=\"1\" colspan=\"1\"/><th align=\"left\" rowspan=\"1\" colspan=\"1\">Total (N=24&#8201;075)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">SVS (n=270, 1.1)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">PVS (n=10&#8201;195, 42.3%)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">AVS (n=13&#8201;610, 56.5%)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">\n<italic toggle=\"yes\">P</italic> value</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Age, y</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">71.1&#177;11.8</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">65.9&#177;13.5</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">70.1&#177;11.7</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">72&#177;11.7</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Female sex</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9371 (38.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">84 (31.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">4007 (39.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">5280 (38.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.022</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">White race</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">21&#8201;917 (91)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">247 (91.5)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9425 (92.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">12&#8201;245 (90)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" colspan=\"6\" rowspan=\"1\">Census region</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Midwest</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">11&#8201;853 (49.2)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">143 (53)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">4987 (48.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6723 (49.4)</td><td align=\"left\" rowspan=\"4\" colspan=\"1\">0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Northeast</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">5467 (22.7)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">78 (28.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2383 (23.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3006 (22.1)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">South</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">5158 (21.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">35 (13)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2148 (21.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2975 (21.9)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">West</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1597 (6.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">14 (5.2)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">677 (6.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">906 (6.7)</td></tr><tr><td align=\"left\" colspan=\"6\" rowspan=\"1\">Payor</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Commercial</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">7395 (30.7)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">130 (48.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3579 (35.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3686 (27.1)</td><td align=\"left\" rowspan=\"3\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Medicare</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">15&#8201;609 (64.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">133 (49.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6242 (61.2)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9234 (67.8)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Medicaid</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1071 (4.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">7 (2.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">374 (3.7)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">690 (5.1)</td></tr><tr><td align=\"left\" colspan=\"6\" rowspan=\"1\">Comorbidities</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Hypertension</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">21&#8201;863 (90.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">187 (69.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8976 (88)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">12&#8201;700 (93.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Diabetes</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">10&#8201;238 (42.5)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">67 (24.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3902 (38.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6269 (46.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Atrial fibrillation/flutter</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8645 (35.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">35 (13)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1902 (18.7)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6708 (49.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">HFpEF or HFrEF</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">11&#8201;518 (47.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0 (0)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2067 (20.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9451 (69.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Stroke/TIA</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2748 (11.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">15 (5.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">847 (8.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1886 (13.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">ESRD or CKD on dialysis</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">858 (3.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0 (0)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">128 (1.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">730 (5.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">COPD with O<sub>2</sub> dependence</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">840 (3.5)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0 (0)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">116 (1.1)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">724 (5.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Prior PCI</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2340 (9.7)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">7 (2.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">641 (6.3)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1692 (12.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Prior CABG</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3327 (13.8)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">31 (11.5)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1721 (16.9)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1575 (11.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" colspan=\"6\" rowspan=\"1\">Comorbidity scores</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">Elixhauser score</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9.2&#177;3.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6.5&#177;2.7</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8.1&#177;2.8</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">10.1&#177;3.3</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">HFRS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">15.9&#177;11.1</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">9.4&#177;5.6</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">12&#177;8</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">18.9&#177;12.2</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">TAVR</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">13&#8201;483 (56)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">115 (42.6)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">5035 (49.4)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8333 (61.2)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td></tr></tbody></table><table-wrap-foot id=\"jah311439-ntgp-0002\"><fn id=\"jah311439-note-0004\"><p>Values are mean&#177;SD or n (%).</p></fn><fn id=\"jah311439-note-0005\"><p>AVS indicates acute valve syndrome; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end&#8208;stage renal disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFRS, Hospital Frailty Risk Score; PCI, percutaneous coronary intervention; PVS, progressive valve syndrome; SVS, stable valve syndrome; TAVR, transcatheter aortic valve replacement; and TIA, transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></sec><sec id=\"jah311439-sec-0017\"><title>Clinical Outcomes</title><p>One&#8208;year unadjusted all&#8208;cause death was highest in patients with AVS (AVS 11.0% versus 4.7% PVS and 1.5% SVS; AVS adjusted HR [aHR], 2.9 [95% CI, 1.1&#8211;7.8]; <italic toggle=\"yes\">P</italic>=0.03 compared with SVS; Figure&#160;<xref rid=\"jah311439-fig-0002\" ref-type=\"fig\">2A</xref>). Unadjusted HFH rates were also higher among patients with AVS (AVS 12.8%, PVS 4.2%, SVS 1.6%; aHR for AVS, 4.1 [95% CI, 1.6&#8211;11.1]; <italic toggle=\"yes\">P</italic>=0.005 compared with SVS; Figure&#160;<xref rid=\"jah311439-fig-0002\" ref-type=\"fig\">2B</xref>). The unadjusted rate of the composite outcome of death or HFH was 20.2% in AVS, 7.8% in PVS, and 2.7% in SVS (aHR for AVS, 3.6 [95% CI, 1.7&#8211;7.6]; <italic toggle=\"yes\">P</italic>&lt;0.001 compared with SVS; Figure&#160;<xref rid=\"jah311439-fig-0002\" ref-type=\"fig\">2C</xref>). Stroke or transient ischemic attack risk was quantitatively highest in patients with AVS, but the difference from SVS was not significant (unadjusted rates AVS 6.5% versus PVS 4.2% versus 4.4% SVS; aHR for AVS, 0.9 [95% CI, 0.5&#8211;1.7]; <italic toggle=\"yes\">P</italic>=0.74; Figure&#160;<xref rid=\"jah311439-fig-0002\" ref-type=\"fig\">2D</xref>).</p><fig position=\"float\" fig-type=\"Figure\" id=\"jah311439-fig-0002\" orientation=\"portrait\"><label>Figure 2</label><caption><title>Clinical outcomes 1 year after aortic valve replacement according to clinical presentation.</title><p>\n<bold>A</bold>, All&#8208;cause death. <bold>B</bold>, HF hospitalization. <bold>C</bold>, Death or HF hospitalization. <bold>D</bold>, Stroke or TIA. aHR indicates adjusted hazard ratio; AVR, aortic valve replacement; AVS, acute valve syndrome; HF, heart failure; PVS, progressive valve syndrome; and TIA, transient ischemic attack.</p></caption><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" position=\"anchor\" id=\"jats-graphic-5\" orientation=\"portrait\" xlink:href=\"JAH3-14-e043486-g001.jpg\"/></fig></sec><sec id=\"jah311439-sec-0018\"><title>Health Care Costs and Resource Use</title><p>Figure&#160;<xref rid=\"jah311439-fig-0003\" ref-type=\"fig\">3</xref> shows risk&#8208;adjusted health care costs and inpatient hospitalizations per clinical presentation group during the follow&#8208;up (AVR hospitalization + 1 year) period. Health care costs showed an increasing trend across presentation groups, with total index plus first&#8208;year costs of $146&#8201;309 for SVS, $173&#8201;719 for PVS, and $182&#8201;576 for AVS (<italic toggle=\"yes\">P</italic>\n<sub>trend</sub>&lt;0.001) (Table&#160;<xref rid=\"jah311439-tbl-0002\" ref-type=\"table\">2</xref>). Total costs were significantly higher for AVS (+$36&#8201;267 [95% CI, $22&#8201;302&#8211;$50 232]; <italic toggle=\"yes\">P</italic>&lt;0.001) and PVS (+$27&#8201;410 [95% CI, $13&#8201;507&#8211;$41314]; <italic toggle=\"yes\">P</italic>&lt;0.001) as compared with patients with SVS. For the index AVR, hospitalization costs increased from $88&#8201;065 in patients with SVS to $99&#8201;248 in patients with PVS and $101&#8201;150 in patients with AVS (<italic toggle=\"yes\">P</italic>\n<sub>trend</sub>=0.007).</p><fig position=\"float\" fig-type=\"Figure\" id=\"jah311439-fig-0003\" orientation=\"portrait\"><label>Figure 3</label><caption><title>AVR&#8208;related health care costs per clinical presentation.</title><p>Follow&#8208;up costs are for time 0 (cost of procedure) plus 1 year following the procedure. <italic toggle=\"yes\">P</italic>\n<sub>trend</sub> of total follow&#8208;up cost (<italic toggle=\"yes\">P</italic>\n<sub>trend</sub>&lt;0.001) and total follow&#8208;up hospitalization (<italic toggle=\"yes\">P</italic>\n<sub>trend</sub>&lt;0.001) were all statistically significant. AVR indicates aortic valve replacement; AVS, acute valve syndrome; PVS, progressive valve syndrome; and SVS, stable valve syndrome.</p></caption><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" position=\"anchor\" id=\"jats-graphic-7\" orientation=\"portrait\" xlink:href=\"JAH3-14-e043486-g003.jpg\"/></fig><table-wrap position=\"float\" id=\"jah311439-tbl-0002\" content-type=\"Table\" orientation=\"portrait\"><label>Table 2</label><caption><p>Health Care Costs and Resource Use by Patient Group</p></caption><table frame=\"hsides\" rules=\"groups\"><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><thead><tr style=\"border-bottom:solid 1px #000000\"><th align=\"left\" rowspan=\"1\" colspan=\"1\">Cost outcomes and group</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Estimate</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Diff (95% CI)</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">\n<italic toggle=\"yes\">P</italic> value</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">RR (95% CI)</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Total costs (AVR&#8201;+&#8201;1 y after)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$146&#8201;309</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$173&#8201;719</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$27&#8201;410 ($13 507&#8211;$41&#8201;314)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.19 (1.08&#8211;1.31)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$182&#8201;576</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$36&#8201;267 ($22 302&#8211;$50&#8201;232)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.25 (1.13&#8211;1.37)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">AVR hospitalization costs</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.007<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$88&#8201;065</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$99&#8201;248</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$11&#8201;183 ($3597&#8211;$18&#8201;768)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.004</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.13 (1.03&#8211;1.23)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$101&#8201;150</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$13&#8201;084 ($5468&#8211;$20&#8201;701)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.15 (1.05&#8211;1.25)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">1&#8208;y follow&#8208;up costs</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$54&#8201;136</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$73&#8201;781</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$19&#8201;645 ($9445&#8211;$29&#8201;844)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.36 (1.13&#8211;1.64)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$80&#8201;445</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">$26&#8201;309 ($16 073&#8211;$36&#8201;545)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.49 (1.23&#8211;1.79)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">AVR hospitalization length of stay, d</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6.46</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">7.30</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.85 (0.18&#8211;1.52)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.013</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.13 (1.02&#8211;1.25)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8.62</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2.16 (1.49&#8211;2.83)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.33 (1.20&#8211;1.48)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">All&#8208;cause hospitalization (1 y after)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.81</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.05</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.24 (0.04&#8211;0.43)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.019</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.29 (1.01&#8211;1.64)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.27</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.46 (0.26&#8211;0.65)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.56 (1.23&#8211;1.98)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">HF hospitalization (1 y after)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.04</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.08</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.045 (0.01&#8211;0.08)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.018</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2.17 (0.84&#8211;5.64)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.19</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.147 (0.11&#8211;0.18)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">4.86 (1.88&#8211;12.59)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">Inpatient d (1 y after)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6.24</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">7.36</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.13 (&#8722;0.79 to 3.04)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.25</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.18 (0.87&#8211;1.60)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">8.99</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">2.75 (0.82&#8211;4.68)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.005</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.44 (1.06&#8211;1.96)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\">HF inpatient d (1 y after)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001<xref rid=\"jah311439-note-0007\" ref-type=\"table-fn\">*</xref>\n</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">SVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.28</td><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/><td align=\"left\" rowspan=\"1\" colspan=\"1\"/></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">PVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.87</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">0.59 (0.31&#8211;0.86)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">3.1 (1.28&#8211;7.50)</td></tr><tr><td align=\"left\" style=\"padding-left:10%\" rowspan=\"1\" colspan=\"1\">AVS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.93</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">1.66 (1.32&#8211;1.99)</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">&lt;0.001</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">6.92 (2.86&#8211;16.76)</td></tr></tbody></table><table-wrap-foot id=\"jah311439-ntgp-0003\"><fn id=\"jah311439-note-0006\"><p>AVR indicates aortic valve replacement; AVS, acute valve syndrome; Diff, difference;&#160;HF, heart failure; PVS, progressive valve syndrome; RR, risk ratio; and SVS, stable valve syndrome.</p></fn><fn id=\"jah311439-note-0007\"><label>*</label><p>Indicates <italic toggle=\"yes\">P</italic>\n<sub>trend</sub>.</p></fn></table-wrap-foot></table-wrap><p>Resource use also increased with acuity of clinical presentation at AVR (Table&#160;<xref rid=\"jah311439-tbl-0002\" ref-type=\"table\">2</xref>). Length of stay for index AVR increased progressively (SVS: 6.46&#8201;days; PVS: 7.30&#8201;days; AVS: 8.62&#8201;days; <italic toggle=\"yes\">P</italic>\n<sub>trend</sub>&lt;0.001). One&#8208;year rehospitalizations demonstrated consistent results, from 0.81 hospitalizations in patients with SVS to 1.05 in patients with PVS and 1.27 in patients with AVS (<italic toggle=\"yes\">P</italic>\n<sub>trend</sub>&lt;0.001). Patients with AVS experienced significantly more all&#8208;cause hospitalizations (1.27 versus 0.81; adjusted incident rate ratio [aIRR] for AVS, 1.6 [95% CI, 1.2&#8211;1.9]; <italic toggle=\"yes\">P</italic>&lt;0.001) and HFH (0.19 versus 0.04; aIRR for AVS, 4.86 [95% CI, 1.9&#8211;12.6]; <italic toggle=\"yes\">P</italic>&lt;0.001) compared with patients with SVS. The difference was particularly pronounced for HF&#8208;related inpatient days (1.93 versus 0.28&#8201;days; aIRR, 6.92 [95% CI, 2.9&#8211;16.7]; <italic toggle=\"yes\">P</italic>&lt;0.001).</p></sec><sec id=\"jah311439-sec-0019\"><title>Post Hoc Analyses</title><p>The association between clinical presentation and HFH was also found when limiting the follow&#8208;up to the first 30&#8208;days following AVR discharge. Both AVS (adjusted odds ratio [aOR], 11.20 [95% CI, 0.7&#8211;178.13]; <italic toggle=\"yes\">P</italic>&lt;0.001) and PVS (aOR, 5.42 [95% CI, 0.34&#8211;86.49]; <italic toggle=\"yes\">P</italic>&lt;0.001) were associated with significantly higher odds of HFH within 30&#8201;days compared with patients with patients with SVS (Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S2</xref>).</p><p>AVR hospitalization cost patterns differed between SAVR and TAVR cohorts (Table&#160;<xref rid=\"jah311439-supitem-0001\" ref-type=\"supplementary-material\">S3</xref>). SAVR showed modest cost increases for patients with SVS to AVS (difference, $11&#8201;081; <italic toggle=\"yes\">P</italic>=0.05), whereas TAVR showed larger relative differences between SVS and both PVS (difference, $15&#8201;508; <italic toggle=\"yes\">P</italic>&lt;0.01) and AVS (difference, $14&#8201;070; <italic toggle=\"yes\">P</italic>&lt;0.01). Length of stay patterns were consistent across both procedures.</p></sec></sec><sec sec-type=\"discussion\" id=\"jah311439-sec-0020\"><title>DISCUSSION</title><p>Derived from a large, real&#8208;world claims database, the current study confirms the detrimental impact of AVS before AVR (TAVR or SAVR) and demonstrates, for the first time, its association with increased health care costs and resource use. Presentation with AVS was the most frequent mode of clinical presentation before AVR, with 56.5% of patients presenting with AVS compared with 42.3% with PVS and 1.2% with SVS. AVS presentation demonstrated the worst clinical outcomes 1 year after AVR, with increased risk of mortality and HFH. Patients undergoing AVR while still asymptomatic (SVS) demonstrated the best clinical outcomes after AVR. Similarly, for cost and use outcomes, AVS was associated with significant increases in health care cost, length of stay, and resource use up to 1 year after AVR, whereas patients with SVS had the lowest cost and resource use after AVR. The hospitalization costs for AVR were found to be the lowest at SVS for both TAVR and SAVR procedures. When comparing AVR hospitalization cost of SVS with those of PVS and AVS, higher absolute cost savings was observed for patients undergoing TAVR. These results underscore that the cost of AVR hospitalization is generally lower for TAVR compared with SAVR, and that significant cost savings can be achieved by intervening before the onset of symptoms.</p><p>Recent evidence suggests that a strategy of early intervention (TAVR or SAVR) versus clinical surveillance is associated with improved outcomes for patients presenting with severe AS and no symptoms.<xref rid=\"jah311439-bib-0002\" ref-type=\"bibr\">\n<sup>2</sup>\n</xref>, <xref rid=\"jah311439-bib-0005\" ref-type=\"bibr\">\n<sup>5</sup>\n</xref>, <xref rid=\"jah311439-bib-0006\" ref-type=\"bibr\">\n<sup>6</sup>\n</xref>, <xref rid=\"jah311439-bib-0007\" ref-type=\"bibr\">\n<sup>7</sup>\n</xref>, <xref rid=\"jah311439-bib-0008\" ref-type=\"bibr\">\n<sup>8</sup>\n</xref>, <xref rid=\"jah311439-bib-0009\" ref-type=\"bibr\">\n<sup>9</sup>\n</xref> Our findings are consistent, suggesting that intervention while patients are still stable and asymptomatic may prevent the occurrence of AVS and preclude subsequent mortality, morbidity, and health care costs. The recent Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY&#8208;TAVR) trial demonstrated the superiority of early intervention with TAVR compared with clinical surveillance for patients with asymptomatic severe AS, a benefit that was mainly driven by unplanned cardiovascular hospitalization. Further assessment of patients randomized to clinical surveillance and eventually converted to AVR demonstrated that &#8776;40% of those patients experienced AVS before AVR, with severe symptoms such as NYHA III&#8211;IV, HFH, or syncope. Approximatively 60% of patients included in our study presented with AVS before AVR, which reflects the real&#8208;world nature of our study, with follow&#8208;up and clinical surveillance less optimal than the level performed in the randomized trial. Similarly, data from the Society of Thoracic Surgeons&#8211;American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC/TVT) demonstrated that up to 70% of patients undergo AVR while in NYHA class III&#8211;IV.<xref rid=\"jah311439-bib-0010\" ref-type=\"bibr\">\n<sup>10</sup>\n</xref>, <xref rid=\"jah311439-bib-0011\" ref-type=\"bibr\">\n<sup>11</sup>\n</xref> Given the detrimental impact on clinical and economic outcomes associated with undergoing AVR while presenting with AVS and PVS compared with SVS, a strategy of early intervention seems to be preferable among patients with severe asymptomatic AS.</p><p>Presentation with AVS before AVR was associated with significantly higher costs during the index hospitalization ($101&#8201;150 AVS versus $88&#8201;065 SVS) and throughout the following year compared with patients with SVS. AVS was associated with stepwise increases in health care use, particularly for heart failure&#8208;related care, with patients with AVS experiencing nearly 5 times more HFH than patients with SVS. Similarly, AVS presentation was associated with a $36&#8201;000 increase in total cost during the first year post&#8208;AVR. These findings are important and suggest that early treatment could yield significant cost savings. These results complement previous studies examining the economic impact of delayed intervention in AS. Sethi et&#160;al found that delaying TAVR for a year was associated with an incremental cost of $9240 on average.<xref rid=\"jah311439-bib-0012\" ref-type=\"bibr\">\n<sup>12</sup>\n</xref> Chen et&#160;al demonstrated that acute HFH before AVR was associated with &#8776;30% higher costs,<xref rid=\"jah311439-bib-0013\" ref-type=\"bibr\">\n<sup>13</sup>\n</xref> whereas our more comprehensive clinical presentation assessment reveals even larger cost differentials when considering the full spectrum of disease progression. Similarly, our findings support Wald's observation that acute decompensation in AS leads to substantially higher resource use,<xref rid=\"jah311439-bib-0014\" ref-type=\"bibr\">\n<sup>14</sup>\n</xref> though we now demonstrate that&#160;this effect persists well beyond the initial hospitalization.</p><sec id=\"jah311439-sec-0021\"><title>Limitations</title><p>Several limitations should be considered when interpreting our findings. First, the identification of asymptomatic patients through claims and EHR data presents inherent challenges because clinicians rarely document the absence of symptoms. This resulted in a relatively small asymptomatic cohort (n=270), leading to less precise estimates for this group compared with patients with PVS and AVS. Although our methodology for identifying truly asymptomatic patients is robust, the small sample size warrants cautious interpretation of the magnitude of differences among groups. The use of administrative claims, EHR data, and physician notes to classify disease severity has inherent limitations. Missing documentation, variability in coding practices, and inconsistent terminology in clinical notes may lead to misclassification of patients' clinical presentation. NLP of clinical notes, although advanced, may not capture all nuances of symptom description. Additionally, the temporal relationship between symptom onset and documentation may not always be precise in claims&#8208;based analyses. The Market Clarity database, although comprehensive, may not be fully representative of the broader AS population undergoing AVR. The database includes only patients from participating health care systems and insurers, potentially limiting generalizability. Socioeconomic and geographic factors influencing access to participating health care systems could introduce selection bias. Furthermore, variations in coding practices and documentation standards across health care systems may affect the consistency of our severity classifications.</p></sec></sec><sec sec-type=\"conclusions\" id=\"jah311439-sec-0022\"><title>CONCLUSIONS</title><p>AVS was the most frequent mode of presentation before AVR and was associated with increases in death, HFH, health care costs, and resource use 1 year after AVR compared with patients undergoing AVR while presenting with SVS. These findings extend beyond previous work by quantifying the substantial economic burden of delayed intervention and suggest potential cost savings of early intervention while patients are still stable and asymptomatic.</p></sec><sec id=\"jah311439-sec-0023\"><title>Source of Funding</title><p>None.</p></sec><sec sec-type=\"COI-statement\" id=\"jah311439-sec-0024\"><title>Disclosures</title><p>Dr G&#233;n&#233;reux is a consultant for Abbott Vascular; principal investigator of the Eclipse Trial (sponsored by Abbott Vascular); a consultant, advisor, and proctor for Edwards Lifesciences; the principal investigator for the EARLY&#8208;TAVR trial and Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS) trial (sponsored by Edwards Lifesciences); a consultant for egnite; a consultant for Medtronic; a consultant for and received equity from Pi&#8208;Cardia; a consultant for and received equity from Puzzle Medical; and a consultant for 4C Medical. Dr Baron received institutional research support from Acarix, received institutional research support from Abiomed, is a consultant for Boston Scientific, received institutional research support from Pi&#8208;Cardia (ShortCut trial), is on the advisory board and received speaking honoraria from Edwards Lifesciences, is on the advisory board and is a consultant and received speaking honoraria from Medtronic, is on the advisory board and received speaking honoraria from Zoll Medical, and received speaking honoraria and consultation fees from Shockwave Medical. A. Dratch, S. Murphy, and Dr Chikermane are employees of Edwards Lifesciences. The remaining authors have no disclosures to report.</p></sec><sec sec-type=\"supplementary-material\"><title>Supporting information</title><supplementary-material id=\"jah311439-supitem-0001\" position=\"float\" content-type=\"local-data\" orientation=\"portrait\"><caption><p>Tables S1&#8211;S3</p><p>Data S1</p></caption><media xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"JAH3-14-e043486-s001.pdf\" position=\"float\" orientation=\"portrait\"/></supplementary-material></sec></body><back><ref-list content-type=\"cited-references\" id=\"jah311439-bibl-0001\"><title>References</title><ref id=\"jah311439-bib-0001\"><label>1</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0001\"><string-name name-style=\"western\"><surname>Genereux</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Lindman</surname><given-names>BR</given-names></string-name>, <string-name name-style=\"western\"><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Garcia</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Koulogiannis</surname><given-names>KP</given-names></string-name>, <string-name name-style=\"western\"><surname>Rodriguez</surname><given-names>E</given-names></string-name>, <string-name name-style=\"western\"><surname>Thourani</surname><given-names>VH</given-names></string-name>, <string-name name-style=\"western\"><surname>Giustino</surname><given-names>G</given-names></string-name>, <string-name name-style=\"western\"><surname>Sharma</surname><given-names>RP</given-names></string-name>, <string-name name-style=\"western\"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, et&#160;al. <article-title>Acute valve syndrome in aortic stenosis</article-title>. <source>Structural Heart</source>. <year>2024</year>;<volume>9</volume>:<fpage>100377</fpage>. doi: <pub-id pub-id-type=\"doi\">10.1016/j.shj.2024.100377</pub-id><pub-id pub-id-type=\"pmid\">40321310</pub-id><pub-id pub-id-type=\"pmcid\">PMC12047511</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0002\"><label>2</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0002\"><string-name name-style=\"western\"><surname>Genereux</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Schwartz</surname><given-names>A</given-names></string-name>, <string-name name-style=\"western\"><surname>Oldemeyer</surname><given-names>JB</given-names></string-name>, <string-name name-style=\"western\"><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style=\"western\"><surname>Blanke</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Lindman</surname><given-names>BR</given-names></string-name>, <string-name name-style=\"western\"><surname>Babaliaros</surname><given-names>V</given-names></string-name>, <string-name name-style=\"western\"><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name name-style=\"western\"><surname>Daniels</surname><given-names>DV</given-names></string-name>, et&#160;al. <article-title>Transcatheter aortic&#8208;valve replacement for asymptomatic severe aortic stenosis</article-title>. <source>N Engl J Med</source>. <year>2024</year>;<volume>392</volume>:<fpage>217</fpage>&#8211;<lpage>227</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1056/NEJMoa2405880</pub-id><pub-id pub-id-type=\"pmid\">39466903</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0003\"><label>3</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0003\"><string-name name-style=\"western\"><surname>Elixhauser</surname><given-names>A</given-names></string-name>, <string-name name-style=\"western\"><surname>Steiner</surname><given-names>C</given-names></string-name>, <string-name name-style=\"western\"><surname>Harris</surname><given-names>DR</given-names></string-name>, <string-name name-style=\"western\"><surname>Coffey</surname><given-names>RM</given-names></string-name>. <article-title>Comorbidity measures for use with administrative data</article-title>. <source>Med Care</source>. <year>1998</year>;<volume>36</volume>:<fpage>8</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1097/00005650-199801000-00004</pub-id><pub-id pub-id-type=\"pmid\">9431328</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0004\"><label>4</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0004\"><string-name name-style=\"western\"><surname>Gilbert</surname><given-names>T</given-names></string-name>, <string-name name-style=\"western\"><surname>Neuburger</surname><given-names>J</given-names></string-name>, <string-name name-style=\"western\"><surname>Kraindler</surname><given-names>J</given-names></string-name>, <string-name name-style=\"western\"><surname>Keeble</surname><given-names>E</given-names></string-name>, <string-name name-style=\"western\"><surname>Smith</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Ariti</surname><given-names>C</given-names></string-name>, <string-name name-style=\"western\"><surname>Arora</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Street</surname><given-names>A</given-names></string-name>, <string-name name-style=\"western\"><surname>Parker</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Roberts</surname><given-names>HC</given-names></string-name>, et&#160;al. <article-title>Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>1775</fpage>&#8211;<lpage>1782</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1016/S0140-6736(18)30668-8</pub-id><pub-id pub-id-type=\"pmid\">29706364</pub-id><pub-id pub-id-type=\"pmcid\">PMC5946808</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0005\"><label>5</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0005\"><string-name name-style=\"western\"><surname>Kang</surname><given-names>DH</given-names></string-name>, <string-name name-style=\"western\"><surname>Park</surname><given-names>SJ</given-names></string-name>, <string-name name-style=\"western\"><surname>Lee</surname><given-names>SA</given-names></string-name>, <string-name name-style=\"western\"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name name-style=\"western\"><surname>Kim</surname><given-names>HK</given-names></string-name>, <string-name name-style=\"western\"><surname>Yun</surname><given-names>SC</given-names></string-name>, <string-name name-style=\"western\"><surname>Hong</surname><given-names>GR</given-names></string-name>, <string-name name-style=\"western\"><surname>Song</surname><given-names>JM</given-names></string-name>, <string-name name-style=\"western\"><surname>Chung</surname><given-names>CH</given-names></string-name>, et&#160;al. <article-title>Early surgery or conservative Care for Asymptomatic Aortic Stenosis</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>111</fpage>&#8211;<lpage>119</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1056/NEJMoa1912846</pub-id><pub-id pub-id-type=\"pmid\">31733181</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0006\"><label>6</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0006\"><string-name name-style=\"western\"><surname>Banovic</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Putnik</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Da Costa</surname><given-names>BR</given-names></string-name>, <string-name name-style=\"western\"><surname>Penicka</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Deja</surname><given-names>MA</given-names></string-name>, <string-name name-style=\"western\"><surname>Kotrc</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Kockova</surname><given-names>R</given-names></string-name>, <string-name name-style=\"western\"><surname>Glaveckaite</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Gasparovic</surname><given-names>H</given-names></string-name>, <string-name name-style=\"western\"><surname>Pavlovic</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long&#8208;term follow&#8208;up of the AVATAR trial</article-title>. <source>Eur Heart J</source>. <year>2024</year>;<volume>45</volume>:<fpage>4526</fpage>&#8211;<lpage>4535</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1093/eurheartj/ehae585</pub-id><pub-id pub-id-type=\"pmid\">39217448</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0007\"><label>7</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0007\"><string-name name-style=\"western\"><surname>Loganath</surname><given-names>K</given-names></string-name>, <string-name name-style=\"western\"><surname>Craig</surname><given-names>NJ</given-names></string-name>, <string-name name-style=\"western\"><surname>Everett</surname><given-names>RJ</given-names></string-name>, <string-name name-style=\"western\"><surname>Bing</surname><given-names>R</given-names></string-name>, <string-name name-style=\"western\"><surname>Tsampasian</surname><given-names>V</given-names></string-name>, <string-name name-style=\"western\"><surname>Molek</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Botezatu</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Aslam</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Lewis</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Graham</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial</article-title>. <source>JAMA</source>. <year>2024</year>;<volume>333</volume>:<fpage>213</fpage>&#8211;<lpage>221</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1001/jama.2024.22730</pub-id><pub-id pub-id-type=\"pmcid\">PMC11519785</pub-id><pub-id pub-id-type=\"pmid\">39466640</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0008\"><label>8</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0008\"><string-name name-style=\"western\"><surname>Genereux</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Banovic</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Kang</surname><given-names>DH</given-names></string-name>, <string-name name-style=\"western\"><surname>Giustino</surname><given-names>G</given-names></string-name>, <string-name name-style=\"western\"><surname>Prendergast</surname><given-names>BD</given-names></string-name>, <string-name name-style=\"western\"><surname>Lindman</surname><given-names>BR</given-names></string-name>, <string-name name-style=\"western\"><surname>Newby</surname><given-names>DE</given-names></string-name>, <string-name name-style=\"western\"><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style=\"western\"><surname>Craig</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: a systematic review and meta&#8208;analysis</article-title>. <source>J Am Coll Cardiol</source>. <year>2024</year>;<volume>85</volume>:<fpage>912</fpage>&#8211;<lpage>922</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1016/j.jacc.2024.11.006</pub-id><pub-id pub-id-type=\"pmid\">39641732</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0009\"><label>9</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0009\"><string-name name-style=\"western\"><surname>Lindman</surname><given-names>BR</given-names></string-name>, <string-name name-style=\"western\"><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name name-style=\"western\"><surname>Pellikka</surname><given-names>PA</given-names></string-name>. <article-title>Aortic valve replacement for asymptomatic severe aortic stenosis&#8208;the time has come</article-title>. <source>JAMA Cardiol</source>. <year>2025</year>;<volume>10</volume>:<fpage>305</fpage>&#8211;<lpage>306</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1001/jamacardio.2024.5648</pub-id><pub-id pub-id-type=\"pmid\">39937467</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0010\"><label>10</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0010\"><string-name name-style=\"western\"><surname>Arnold</surname><given-names>SV</given-names></string-name>, <string-name name-style=\"western\"><surname>Manandhar</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Vemulapalli</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Kosinski</surname><given-names>AS</given-names></string-name>, <string-name name-style=\"western\"><surname>Batchelor</surname><given-names>WB</given-names></string-name>, <string-name name-style=\"western\"><surname>Thourani</surname><given-names>VH</given-names></string-name>, <string-name name-style=\"western\"><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name name-style=\"western\"><surname>Cohen</surname><given-names>DJ</given-names></string-name>. <article-title>Trends in Transcatheter aortic valve replacement outcomes: insights from the STS/ACC TVT registry</article-title>. <source>JAMA Cardiol</source>. <year>2024</year>;<volume>9</volume>:<fpage>1115</fpage>&#8211;<lpage>1123</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1001/jamacardio.2024.3453</pub-id><pub-id pub-id-type=\"pmid\">39412793</pub-id><pub-id pub-id-type=\"pmcid\">PMC11581560</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0011\"><label>11</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0011\"><string-name name-style=\"western\"><surname>Arnold</surname><given-names>SV</given-names></string-name>, <string-name name-style=\"western\"><surname>Manandhar</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Vemulapalli</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Vekstein</surname><given-names>AM</given-names></string-name>, <string-name name-style=\"western\"><surname>Kosinski</surname><given-names>AS</given-names></string-name>, <string-name name-style=\"western\"><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name name-style=\"western\"><surname>Cohen</surname><given-names>DJ</given-names></string-name>. <article-title>Patient&#8208;reported vs. physician&#8208;estimated symptoms before and after transcatheter aortic valve replacement</article-title>. <source>Eur Heart J Qual Care Clini Outcomes</source>. <year>2022</year>;<volume>8</volume>:<fpage>161</fpage>&#8211;<lpage>168</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1093/ehjqcco/qcab078</pub-id><pub-id pub-id-type=\"pmid\">34718485</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0012\"><label>12</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0012\"><string-name name-style=\"western\"><surname>Sethi</surname><given-names>A</given-names></string-name>, <string-name name-style=\"western\"><surname>Elmariah</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Gunnarsson</surname><given-names>C</given-names></string-name>, <string-name name-style=\"western\"><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Chikermane</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Thompson</surname><given-names>C</given-names></string-name>, <string-name name-style=\"western\"><surname>Russo</surname><given-names>M</given-names></string-name>. <article-title>The cost of waiting for a Transcatheter aortic valve replacement in Medicare beneficiaries with severe aortic stenosis</article-title>. <source>Structural Heart</source>. <year>2024</year>;<volume>8</volume>:<elocation-id>100321</elocation-id>. doi: <pub-id pub-id-type=\"doi\">10.1016/j.shj.2024.100321</pub-id><pub-id pub-id-type=\"pmid\">39670051</pub-id><pub-id pub-id-type=\"pmcid\">PMC11632791</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0013\"><label>13</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0013\"><string-name name-style=\"western\"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style=\"western\"><surname>Crowley</surname><given-names>A</given-names></string-name>, <string-name name-style=\"western\"><surname>Ben&#8208;Yehuda</surname><given-names>O</given-names></string-name>, <string-name name-style=\"western\"><surname>Summers</surname><given-names>M</given-names></string-name>, <string-name name-style=\"western\"><surname>Hahn</surname><given-names>RT</given-names></string-name>, <string-name name-style=\"western\"><surname>Jaber</surname><given-names>WA</given-names></string-name>, <string-name name-style=\"western\"><surname>Pibarot</surname><given-names>P</given-names></string-name>, <string-name name-style=\"western\"><surname>Alu</surname><given-names>MC</given-names></string-name>, <string-name name-style=\"western\"><surname>Chau</surname><given-names>KH</given-names></string-name>, et&#160;al. <article-title>Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries</article-title>. <source>Eur J Heart Fail</source>. <year>2020</year>;<volume>22</volume>:<fpage>1866</fpage>&#8211;<lpage>1874</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1002/ejhf.1841</pub-id><pub-id pub-id-type=\"pmid\">32441856</pub-id></mixed-citation></ref><ref id=\"jah311439-bib-0014\"><label>14</label><mixed-citation publication-type=\"journal\" id=\"jah311439-cit-0014\"><string-name name-style=\"western\"><surname>Wald</surname><given-names>DS</given-names></string-name>, <string-name name-style=\"western\"><surname>Williams</surname><given-names>S</given-names></string-name>, <string-name name-style=\"western\"><surname>Bangash</surname><given-names>F</given-names></string-name>, <string-name name-style=\"western\"><surname>Bestwick</surname><given-names>JP</given-names></string-name>. <article-title>Watchful waiting in aortic stenosis: the problem of acute decompensation</article-title>. <source>Am J Med</source>. <year>2018</year>;<volume>131</volume>:<fpage>173</fpage>&#8211;<lpage>177</lpage>. doi: <pub-id pub-id-type=\"doi\">10.1016/j.amjmed.2017.08.027</pub-id><pub-id pub-id-type=\"pmid\">28916422</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>",
  "text": "pmc J Am Heart Assoc J Am Heart Assoc 1888 jaha JAH3 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2047-9980 Wiley PMC12684531 PMC12684531.1 12684531 12684531 41025452 10.1161/JAHA.125.043486 JAH311439 JAHA/2025/043486-T 1 Original Research Original Research Valvular Heart Disease Acute Valve Syndrome Before Aortic Valve Replacement: Impact on Clinical Outcomes, Health Care Costs, and Resource Use Acute Valve Syndrome in Aortic Stenosis Before AVR G&#233;n&#233;reux et&#160;al G&#233;n&#233;reux Philippe MD https://orcid.org/0000-0002-5507-3712 1 philippe.genereux@atlantichealth.org Giustino Gennaro MD 1 Lindman Brian R. MD https://orcid.org/0000-0002-6879-5343 2 Pibarot Philippe DVM, PhD https://orcid.org/0000-0002-3607-279X 3 Baron Suzanne J. MD, MSc https://orcid.org/0000-0002-8319-5637 4 5 Asselin Chantal MD https://orcid.org/0000-0003-2088-2752 1 Dratch Alissa MPH https://orcid.org/0000-0002-2315-979X 6 Murphy Shannon M. E. MA https://orcid.org/0000-0001-7429-9365 6 Chikermane Soumya PhD https://orcid.org/0000-0001-5335-3430 6 Thourani Vinod H. MD 7 Koulogiannis Kostantinos P. MD https://orcid.org/0000-0002-5889-0865 1 Schwartz Allan MD https://orcid.org/0000-0001-5576-2385 8 Leon Martin B. MD https://orcid.org/0000-0002-2002-7492 8 Pellikka Patricia P. MD https://orcid.org/0000-0001-6800-3521 9 Gillam Linda D. MD, MPH https://orcid.org/0000-0002-1716-7574 1 1 Gagnon Cardiovascular Institute, Morristown Medical Center Morristown NJ USA 2 Vanderbilt University Medical Center Nashville TN USA 3 Laval University Quebec City Quebec Canada 4 Massachusetts General Hospital Boston MA USA 5 Baim Institute of Clinical Research Boston MA USA 6 Edwards Lifesciences Irvine CA USA 7 Piedmont Heart and Vascular Institute Atlanta GA USA 8 NewYork&#8208;Presbyterian Hospital/Columbia University Irving Medical Center New York NY USA 9 Mayo Clinic Rochester MN USA * Correspondence to: Philippe G&#233;n&#233;reux, MD, Gagnon Cardiovascular Institute, Morristown Medical Center, 100 Madison Avenue, Morristown, NJ 07960. Email: philippe.genereux@atlantichealth.org 30 9 2025 07 10 2025 14 19 502073 10.1002/jah3.v14.19 e043486 05 5 2025 05 8 2025 30 09 2025 09 12 2025 09 12 2025 &#169; 2025 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made. Impact of Acute Valve Syndrome on Outcomes of Aortic Valve Replacement for&#160;Aortic Stenosis 14 19 30 9 2025 e046270 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 10.1161/JAHA.125.046270 PMC12684557 41025497 Background A classification system describing clinical presentation before aortic valve replacement (AVR) has recently been proposed (stable valve syndrome [SVS]), mildly symptomatic (progressive valve syndrome), or with acute and severe signs and symptoms (acute valve syndrome [AVS]). We aimed to evaluate the clinical impact, health care costs, and resource use associated with the mode of clinical presentation at the time of AVR among patients presenting with aortic stenosis. Methods Using the Market Clarity database (2017&#8211;2023), patients &gt;18&#8201;years old with aortic stenosis and undergoing AVR (transcatheter or surgical) were included. Patients were categorized as SVS, progressive valve syndrome, or AVS based on their clinical presentation during the 1 year before AVR. All&#8208;cause death, heart failure hospitalization, total health care costs (index hospitalization plus 1&#8208;year follow&#8208;up), and resource use were compared across clinical presentation groups using adjusted regression models. Results Of the 24&#8201;075 patients undergoing AVR for aortic stenosis, 270 (1.1%) had SVS, 10 195 (42.3%) progressive valve syndrome, and 13&#8201;610 (56.5%) AVS. Compared with SVS, AVS presentation was associated with increased risk of 1&#8208;year death (adjusted hazard ratio [aHR], 2.93 [95% CI, 1.1&#8211;7.8]; P =0.03) and heart failure hospitalization (aHR, 4.15 [95% CI, 1.6&#8211;11.1]; P &lt;0.01) after AVR. The total costs of AVR and 1&#8208;year follow&#8208;up were significantly higher in both the progressive valve syndrome (difference $27&#8201;410 [$13&#8201;507&#8211;$41&#8201;314]) and AVS groups (difference $36&#8201;267 [$22&#8201;302&#8211;$50&#8201;232]) compared with patients with SVS. Conclusions AVS was frequent among patients undergoing AVR and was associated with increase in death, heart failure hospitalization, health care costs, and resource use 1 year after AVR, and SVS presentation was associated with the best clinical and economic outcomes. acute valve syndrome aortic stenosis aortic valve replacement asymptomatic health care cost Subject Categories Aortic Valve Replacement/Transcather Aortic Valve Implantation Cardiovascular Surgery pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date 07 October 2025 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:21.11.2025 This article was sent to Michel Pompeu S&#225;, MD, MSc, MHBA, PhD, FACC, FAHA, Assistant Editor, for review by expert referees, editorial decision, and final disposition. Part of this work was presented as an oral presentation at EuroPCR, May 20&#8211;23, 2025, in Paris, France. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.043486 For Disclosures, see page 10. Nonstandard Abbreviations and Acronyms AS aortic stenosis AVR aortic valve replacement AVS acute valve syndrome HFH heart failure hospitalization NYHA New York Heart Association PVS progressive valve syndrome SAVR surgical aortic valve replacement SVS stable valve syndrome TAVR transcatheter aortic valve replacement Clinical Perspective What Is New? Among patients with aortic stenosis undergoing aortic valve replacement (AVR), presentation with acute and advanced symptoms (acute valve syndrome) is frequent; clinical presentation with acute valve syndrome before AVR is associated with increased mortality and heart failure hospitalization after AVR. Asymptomatic patients (stable valve syndrome) undergoing AVR had the most favorable outcomes after AVR; presentation with acute valve syndrome and progressive valve syndrome is associated with increased health care cost and resource use compared with patients presenting with stable valve syndrome. What Are the Clinical Implications? Based on the worst clinical and economical outcomes associated with acute valve syndrome and progressive valve syndrome presentation, performing AVR when patients with aortic stenosis are stable and with no symptoms (stable valve syndrome) should be the preferred strategy. Aortic stenosis (AS) is a progressive disease characterized by periods of latency and variable evolution. Although some patients have a slow and indolent progression, others present with aggressive disease, with dramatic signs and symptoms. Recently, we proposed a novel classification system describing patients' clinical presentation before aortic valve replacement (AVR). 1 , 2 Patients were categorized into 3 groups based on their clinical presentation before AVR: asymptomatic or stable valve syndrome (SVS); mildly symptomatic or progressive valve syndrome (PVS), such as New York Heart Association (NYHA) class II;&#160;or acute valve syndrome (AVS), such as NYHA class III&#8211;IV, heart failure hospitalization (HFH), syncope, or cardiac arrest. Among a real&#8208;world population of &gt;17&#8201;000 patients undergoing AVR for AS, AVS presentation was associated with a 3&#8208;fold increase in mortality and a 4&#8208;fold increase in risk of HFH 2&#8201;years after AVR compared with patients presenting with no symptoms 1 ; however, those findings have not been confirmed by further research, and the economic impact associated with the mode of clinical presentation before AVR has never been reported. Therefore, using a different patient population, we aimed to (1) externally validate the clinical impact of this new clinical presentation classification and (2) evaluate the health care costs and resources use associated with the mode of clinical presentation before AVR. METHODS Objectives The primary objective of the current study was to assess the clinical impact of the mode of clinical presentation on death and HFH after AVR. We also aimed to quantify differences in total health care costs (index AVR hospitalization plus 1&#8208;year follow&#8208;up) across patients presenting with SVS, PVS, and AVS before AVR. Secondary objectives included comparing patterns of resource use, specifically hospital length of stay, all&#8208;cause hospitalizations, and HFH. We hypothesized that AVS will be associated with worse clinical outcomes compared with SVS, and that health care costs and resource use would demonstrate a stepwise increase with more advanced clinical presentations. Data Source This research made use of Optum's deidentified Market Clarity data, an extensive health care database that integrates data from both Optum&#8208;affiliated and nonaffiliated providers in the United States. The database is derived from longitudinal inpatient and outpatient electronic health record records (EHRs) for 81 million US patients across all 50 states who receive care from 1 of the participating provider organizations. Additionally, a subset of these patients has linked medical and pharmacy claims data. The combined EHR and claims data offer comprehensive information on patient demographics, medical details (such as laboratory test results), procedures, outcomes, and medications, as well as provider information and notes. Natural language processing (NLP) is applied to unstructured clinical notes, enabling extraction of detailed clinical information, including diagnosis codes, symptoms, biomarkers, and laboratory values. The Optum NLP system was developed using vocabulary from the Unified Medical Language System that includes multiple medical dictionaries such as the Logical Observation Identifiers Names and Codes , the Systemized Nomenclature of Medicine&#8208;Clinical Terms , and RxNorm , a listing of generic and branded drugs (among others). NLP concepts are identified and created based on broad topics such as medications, signs, disease and symptoms, measurements, and observations. The data are harvested from the notes fields within the electronic medical records provided to Optum from &gt;50 large health care systems throughout the United States. The data used for development of each NLP concept are deidentified, and accuracy is verified through a series of quality assurance steps before release for use. Each NLP concept included in the data is associated with a unique subject record and a date of observation. For cardiac patients, the Market Clarity database captures detailed clinical parameters including echocardiographic findings, relevant biomarkers, and comprehensive documentation of cardiovascular symptoms and complications. The integrated nature of the data set allows tracking of both clinical outcomes and health care resource use. Coding details are provided in Table&#160; S1 . All data were deidentified and accessed in compliance with the Health Insurance Portability and Accountability Act. As a retrospective analysis of a deidentified database, the research was exempt from institutional review board review under 45 CFR 46.101(b) (4). No informed consent were required. The data that support the findings of this study are available from the corresponding author upon reasonable request. Study Population Adult patients (&#8805;18&#8201;years old) who underwent either transcatheter AVR (TAVR) or surgical AVR (SAVR) for AS between 2017 and 2023 Quater 1&#160;were identified from the Market Clarity database. Eligible patients were required to have continuous medical claims coverage for 1 year before AVR through discharge, and to be enrolled in an integrated delivery network with EHR, claims, and physician records available. Patients with documented moderate or severe aortic regurgitation were excluded. Based on the clinical presentation classification previously published by G&#233;n&#233;reux and colleagues, 1 patients were categorized into 3 groups based on their clinical presentation before AVR: (1) SVS, described as patients with no documented signs or symptoms of AS; (2) PVS, described as patients with NYHA class II symptoms (dyspnea, fatigue, dizziness, angina) or diagnosed diastolic heart failure, edema, or mildly elevated natriuretic peptides (B&#8208;type natriuretic peptide 100&#8211;400 pg/mL or NT&#8208;proBNP [N&#8208;terminal pro&#8208;B&#8208;type natriuretic peptide] 1000&#8211;1500 pg/mL); or (3) AVS, described as NYHA class III&#8211;IV symptoms, HFH, new drop in left ventricular ejection fraction &lt;50%, admission with systolic heart failure, significantly elevated natriuretic peptides (B&#8208;type natriuretic peptide &#8805;400 pg/mL or NT&#8208;proBNP &#8805;1500 pg/mL), new&#8208;onset atrial fibrillation, syncope, cardiogenic shock, or cardiac arrest. Coding details are provided in Table&#160; S1 . Variables of Interest The primary outcomes were all&#8208;cause death, HFH, stroke/transient ischemic attack hospitalization, the composite end point of death or HFH, and total costs (index AVR plus 1&#8208;year follow&#8208;up, annualized), with secondary analyses examining index hospitalization and follow&#8208;up costs separately. Additional 1&#8208;year follow&#8208;up outcomes of interest included total hospitalizations, HFH, total inpatient days, and heart failure inpatient days. The main independent variable was AS presentation category (SVS, PVS, or AVS) as defined previously. 1 Covariates included patient demographics (age, sex, White race, geographic census region, insurance type), procedure type (TAVR versus SAVR), key clinical conditions within the 1&#8208;year baseline period (chronic kidney disease on dialysis, chronic obstructive pulmonary disease with oxygen dependence, prior percutaneous coronary intervention, prior coronary artery bypass grafting), comorbidity measure (Elixhauser comorbidity score), and a measure of frailty (Hospital Frailty Risk Score). The Quan Elixhauser comorbidity score is a validated method for measuring patient comorbidity based on 31 conditions identified from International Classification of Diseases ( ICD ) 9th and 10th revision&#160;diagnosis codes. 3 The score ranges from 0 to 31, with higher scores indicating greater comorbidity burden. The Hospital Frailty Risk Score is a validated score derived from ICD 10th revision diagnosis codes that identifies frail patients at increased risk of adverse events. 4 The score typically ranges from 0 to &gt;20, with scores &gt;5 indicating intermediate risk and scores &gt;15 indicating high risk. Baseline health care costs and use 1 year before the AVR procedure included total health care costs, inpatient days, and all&#8208;cause hospitalizations. Statistical Analysis We performed 4 key time&#8208;to&#8208;event analyses to evaluate clinical outcomes by severity group: time to death, time to first HFH, time to the composite end point of death or HFH, and time to first stroke/transient ischemic attack hospitalization. For outcomes without competing risks (death and composite end point), we generated unadjusted Kaplan&#8208;Meier curves to obtain outcome rates through 1 year and used covariate&#8208;adjusted Cox proportional hazards models to test for differences by clinical presentation. The proportional hazards assumption was assessed using a visual inspection of the Kaplan&#8208;Meier curves and the Schoenfeld residuals test, and there was no meaningful violation of the proportional hazard assumption. When analyzing outcomes with a competing risk of death (HFH and stroke/transient ischemic attack), we used competing risks methodology, using unadjusted cumulative incidence function plots and covariate&#8208;adjusted Fine&#8208;Gray regression modeling of subdistribution hazards. Adjusted hazard ratios are displayed on the Kaplan&#8208;Meier plots, and adjusted subdistribution hazard ratios are displayed on the cumulative incidence plots. For cost and use outcomes, we used generalized linear models to analyze our primary outcome of total costs and secondary outcomes including costs and use during and after the index AVR hospitalization. Each model was run twice: (1) to estimate adjusted mean outcomes by clinical presentation and to calculate the adjusted risk of AVS and PVS compared with SVS (with clinical presentation defined as a categorical variable), and (2) to test if there was a significant linear trend in the outcome across SVS, PVS, and AVS (with clinical presentation defined as a continuous variable and the result reported as P trend ). All adjusted models included covariate adjustment for demographic factors (age, sex, White race), geographic region, insurance type, procedure type (TAVR versus SAVR), clinical risk scores (Elixhauser comorbidity score and frailty score), and key comorbidities, including chronic kidney disease on dialysis, chronic obstructive pulmonary disease on oxygen, prior percutaneous coronary intervention, and prior coronary artery bypass grafting. Outcome modeling was based on a &#947; distribution (costs) or a negative binomial distribution (admission counts and days with overdispersion) and log links. To reduce the impact of extreme values, we trimmed all cost and use outcomes at the 99th percentile within each severity group. In our presentation of results, we report categorical variables as percentage and continuous variables as mean&#177;SD. Statistical significance was defined as P &lt;0.05 for all analyses. Two post hoc analyses were conducted and reported in Tables&#160; S2 and S3 . The first was to assess the association between clinical presentation at AVR and the risk of HFH within 30&#8201;days (Table&#160; S2 ). The odds ratios were calculated using a logistic regression model that incorporated Firth's bias reduction method (penalized maximum likelihood correction). This method was used to produce reasonable estimates, because the asymptomatic group had 0 events. Second, we conducted a stratified analysis of AVR hospitalization cost and AVR length of stay by AVR type to see if the results were observed for both TAVR and SAVR (Table&#160; S3 ). RESULTS Study Population From 2017 to 2023 Quater 1 in the Market Clarity database, 110&#8201;867 patients who underwent AVR procedures for AS were considered for analysis. After systematically excluding patients who were not a part of the Integrated Delivery Network (n=11&#8201;869), lacking complete EHR and claims data (n=7563), missing physician notes (n=12&#8201;319), not continuously enrolled during the baseline year (n=50&#8201;269), or who had a physician note stating presence or absence of moderate or severe aortic regurgitation (n=1973), we then limited the cohort to those &#8805;18&#8201;years old at AVR (n=26&#8201;880). Next, we categorized these patients into SVS, PVS, or AVS based on clinical presentation at AVR; we were unable to categorize 2805 patients due to lack of necessary data. Thus, our final cohort included 24&#8201;075 eligible patients (Figure&#160; 1 ). Of those, 270 (1.1%) presented with SVS before AVR, 10 195 (42.3%) with PVS, and 13&#8201;610 (56.5%) with AVS. TAVR was performed in 13&#8201;483 (56%) patients, and SAVR was performed in 10&#8201;465 (44%) patients. In general, patients presenting with AVS before AVR were older and had more concomitant disease and comorbidities compared with patients with PVS or SVS (Table&#160; 1 ). Women made up 38.9% of the studied population. Figure 1 Study patient attrition diagram. AR indicates aortic regurgitation; AV, aortic valve; AVR, aortic valve replacement; AVS, acute valve syndrome; EHR, electronic health record; and PVS, progressive valve syndrome. Table 1 Baseline Characteristics Total (N=24&#8201;075) SVS (n=270, 1.1) PVS (n=10&#8201;195, 42.3%) AVS (n=13&#8201;610, 56.5%) P value Age, y 71.1&#177;11.8 65.9&#177;13.5 70.1&#177;11.7 72&#177;11.7 &lt;0.001 Female sex 9371 (38.9) 84 (31.1) 4007 (39.3) 5280 (38.8) 0.022 White race 21&#8201;917 (91) 247 (91.5) 9425 (92.4) 12&#8201;245 (90) &lt;0.001 Census region Midwest 11&#8201;853 (49.2) 143 (53) 4987 (48.9) 6723 (49.4) 0.001 Northeast 5467 (22.7) 78 (28.9) 2383 (23.4) 3006 (22.1) South 5158 (21.4) 35 (13) 2148 (21.1) 2975 (21.9) West 1597 (6.6) 14 (5.2) 677 (6.6) 906 (6.7) Payor Commercial 7395 (30.7) 130 (48.1) 3579 (35.1) 3686 (27.1) &lt;0.001 Medicare 15&#8201;609 (64.8) 133 (49.3) 6242 (61.2) 9234 (67.8) Medicaid 1071 (4.4) 7 (2.6) 374 (3.7) 690 (5.1) Comorbidities Hypertension 21&#8201;863 (90.8) 187 (69.3) 8976 (88) 12&#8201;700 (93.3) &lt;0.001 Diabetes 10&#8201;238 (42.5) 67 (24.8) 3902 (38.3) 6269 (46.1) &lt;0.001 Atrial fibrillation/flutter 8645 (35.9) 35 (13) 1902 (18.7) 6708 (49.3) &lt;0.001 HFpEF or HFrEF 11&#8201;518 (47.8) 0 (0) 2067 (20.3) 9451 (69.4) &lt;0.001 Stroke/TIA 2748 (11.4) 15 (5.6) 847 (8.3) 1886 (13.9) &lt;0.001 ESRD or CKD on dialysis 858 (3.6) 0 (0) 128 (1.3) 730 (5.4) &lt;0.001 COPD with O 2 dependence 840 (3.5) 0 (0) 116 (1.1) 724 (5.3) &lt;0.001 Prior PCI 2340 (9.7) 7 (2.6) 641 (6.3) 1692 (12.4) &lt;0.001 Prior CABG 3327 (13.8) 31 (11.5) 1721 (16.9) 1575 (11.6) &lt;0.001 Comorbidity scores Elixhauser score 9.2&#177;3.3 6.5&#177;2.7 8.1&#177;2.8 10.1&#177;3.3 &lt;0.001 HFRS 15.9&#177;11.1 9.4&#177;5.6 12&#177;8 18.9&#177;12.2 &lt;0.001 TAVR 13&#8201;483 (56) 115 (42.6) 5035 (49.4) 8333 (61.2) &lt;0.001 Values are mean&#177;SD or n (%). AVS indicates acute valve syndrome; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end&#8208;stage renal disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFRS, Hospital Frailty Risk Score; PCI, percutaneous coronary intervention; PVS, progressive valve syndrome; SVS, stable valve syndrome; TAVR, transcatheter aortic valve replacement; and TIA, transient ischemic attack. Clinical Outcomes One&#8208;year unadjusted all&#8208;cause death was highest in patients with AVS (AVS 11.0% versus 4.7% PVS and 1.5% SVS; AVS adjusted HR [aHR], 2.9 [95% CI, 1.1&#8211;7.8]; P =0.03 compared with SVS; Figure&#160; 2A ). Unadjusted HFH rates were also higher among patients with AVS (AVS 12.8%, PVS 4.2%, SVS 1.6%; aHR for AVS, 4.1 [95% CI, 1.6&#8211;11.1]; P =0.005 compared with SVS; Figure&#160; 2B ). The unadjusted rate of the composite outcome of death or HFH was 20.2% in AVS, 7.8% in PVS, and 2.7% in SVS (aHR for AVS, 3.6 [95% CI, 1.7&#8211;7.6]; P &lt;0.001 compared with SVS; Figure&#160; 2C ). Stroke or transient ischemic attack risk was quantitatively highest in patients with AVS, but the difference from SVS was not significant (unadjusted rates AVS 6.5% versus PVS 4.2% versus 4.4% SVS; aHR for AVS, 0.9 [95% CI, 0.5&#8211;1.7]; P =0.74; Figure&#160; 2D ). Figure 2 Clinical outcomes 1 year after aortic valve replacement according to clinical presentation. A , All&#8208;cause death. B , HF hospitalization. C , Death or HF hospitalization. D , Stroke or TIA. aHR indicates adjusted hazard ratio; AVR, aortic valve replacement; AVS, acute valve syndrome; HF, heart failure; PVS, progressive valve syndrome; and TIA, transient ischemic attack. Health Care Costs and Resource Use Figure&#160; 3 shows risk&#8208;adjusted health care costs and inpatient hospitalizations per clinical presentation group during the follow&#8208;up (AVR hospitalization + 1 year) period. Health care costs showed an increasing trend across presentation groups, with total index plus first&#8208;year costs of $146&#8201;309 for SVS, $173&#8201;719 for PVS, and $182&#8201;576 for AVS ( P trend &lt;0.001) (Table&#160; 2 ). Total costs were significantly higher for AVS (+$36&#8201;267 [95% CI, $22&#8201;302&#8211;$50 232]; P &lt;0.001) and PVS (+$27&#8201;410 [95% CI, $13&#8201;507&#8211;$41314]; P &lt;0.001) as compared with patients with SVS. For the index AVR, hospitalization costs increased from $88&#8201;065 in patients with SVS to $99&#8201;248 in patients with PVS and $101&#8201;150 in patients with AVS ( P trend =0.007). Figure 3 AVR&#8208;related health care costs per clinical presentation. Follow&#8208;up costs are for time 0 (cost of procedure) plus 1 year following the procedure. P trend of total follow&#8208;up cost ( P trend &lt;0.001) and total follow&#8208;up hospitalization ( P trend &lt;0.001) were all statistically significant. AVR indicates aortic valve replacement; AVS, acute valve syndrome; PVS, progressive valve syndrome; and SVS, stable valve syndrome. Table 2 Health Care Costs and Resource Use by Patient Group Cost outcomes and group Estimate Diff (95% CI) P value RR (95% CI) Total costs (AVR&#8201;+&#8201;1 y after) &lt;0.001 * SVS $146&#8201;309 PVS $173&#8201;719 $27&#8201;410 ($13 507&#8211;$41&#8201;314) &lt;0.001 1.19 (1.08&#8211;1.31) AVS $182&#8201;576 $36&#8201;267 ($22 302&#8211;$50&#8201;232) &lt;0.001 1.25 (1.13&#8211;1.37) AVR hospitalization costs 0.007 * SVS $88&#8201;065 PVS $99&#8201;248 $11&#8201;183 ($3597&#8211;$18&#8201;768) 0.004 1.13 (1.03&#8211;1.23) AVS $101&#8201;150 $13&#8201;084 ($5468&#8211;$20&#8201;701) &lt;0.001 1.15 (1.05&#8211;1.25) 1&#8208;y follow&#8208;up costs &lt;0.001 * SVS $54&#8201;136 PVS $73&#8201;781 $19&#8201;645 ($9445&#8211;$29&#8201;844) &lt;0.001 1.36 (1.13&#8211;1.64) AVS $80&#8201;445 $26&#8201;309 ($16 073&#8211;$36&#8201;545) &lt;0.001 1.49 (1.23&#8211;1.79) AVR hospitalization length of stay, d &lt;0.001 * SVS 6.46 PVS 7.30 0.85 (0.18&#8211;1.52) 0.013 1.13 (1.02&#8211;1.25) AVS 8.62 2.16 (1.49&#8211;2.83) &lt;0.001 1.33 (1.20&#8211;1.48) All&#8208;cause hospitalization (1 y after) &lt;0.001 * SVS 0.81 PVS 1.05 0.24 (0.04&#8211;0.43) 0.019 1.29 (1.01&#8211;1.64) AVS 1.27 0.46 (0.26&#8211;0.65) &lt;0.001 1.56 (1.23&#8211;1.98) HF hospitalization (1 y after) &lt;0.001 * SVS 0.04 PVS 0.08 0.045 (0.01&#8211;0.08) 0.018 2.17 (0.84&#8211;5.64) AVS 0.19 0.147 (0.11&#8211;0.18) &lt;0.001 4.86 (1.88&#8211;12.59) Inpatient d (1 y after) &lt;0.001 * SVS 6.24 PVS 7.36 1.13 (&#8722;0.79 to 3.04) 0.25 1.18 (0.87&#8211;1.60) AVS 8.99 2.75 (0.82&#8211;4.68) 0.005 1.44 (1.06&#8211;1.96) HF inpatient d (1 y after) &lt;0.001 * SVS 0.28 PVS 0.87 0.59 (0.31&#8211;0.86) &lt;0.001 3.1 (1.28&#8211;7.50) AVS 1.93 1.66 (1.32&#8211;1.99) &lt;0.001 6.92 (2.86&#8211;16.76) AVR indicates aortic valve replacement; AVS, acute valve syndrome; Diff, difference;&#160;HF, heart failure; PVS, progressive valve syndrome; RR, risk ratio; and SVS, stable valve syndrome. * Indicates P trend . Resource use also increased with acuity of clinical presentation at AVR (Table&#160; 2 ). Length of stay for index AVR increased progressively (SVS: 6.46&#8201;days; PVS: 7.30&#8201;days; AVS: 8.62&#8201;days; P trend &lt;0.001). One&#8208;year rehospitalizations demonstrated consistent results, from 0.81 hospitalizations in patients with SVS to 1.05 in patients with PVS and 1.27 in patients with AVS ( P trend &lt;0.001). Patients with AVS experienced significantly more all&#8208;cause hospitalizations (1.27 versus 0.81; adjusted incident rate ratio [aIRR] for AVS, 1.6 [95% CI, 1.2&#8211;1.9]; P &lt;0.001) and HFH (0.19 versus 0.04; aIRR for AVS, 4.86 [95% CI, 1.9&#8211;12.6]; P &lt;0.001) compared with patients with SVS. The difference was particularly pronounced for HF&#8208;related inpatient days (1.93 versus 0.28&#8201;days; aIRR, 6.92 [95% CI, 2.9&#8211;16.7]; P &lt;0.001). Post Hoc Analyses The association between clinical presentation and HFH was also found when limiting the follow&#8208;up to the first 30&#8208;days following AVR discharge. Both AVS (adjusted odds ratio [aOR], 11.20 [95% CI, 0.7&#8211;178.13]; P &lt;0.001) and PVS (aOR, 5.42 [95% CI, 0.34&#8211;86.49]; P &lt;0.001) were associated with significantly higher odds of HFH within 30&#8201;days compared with patients with patients with SVS (Table&#160; S2 ). AVR hospitalization cost patterns differed between SAVR and TAVR cohorts (Table&#160; S3 ). SAVR showed modest cost increases for patients with SVS to AVS (difference, $11&#8201;081; P =0.05), whereas TAVR showed larger relative differences between SVS and both PVS (difference, $15&#8201;508; P &lt;0.01) and AVS (difference, $14&#8201;070; P &lt;0.01). Length of stay patterns were consistent across both procedures. DISCUSSION Derived from a large, real&#8208;world claims database, the current study confirms the detrimental impact of AVS before AVR (TAVR or SAVR) and demonstrates, for the first time, its association with increased health care costs and resource use. Presentation with AVS was the most frequent mode of clinical presentation before AVR, with 56.5% of patients presenting with AVS compared with 42.3% with PVS and 1.2% with SVS. AVS presentation demonstrated the worst clinical outcomes 1 year after AVR, with increased risk of mortality and HFH. Patients undergoing AVR while still asymptomatic (SVS) demonstrated the best clinical outcomes after AVR. Similarly, for cost and use outcomes, AVS was associated with significant increases in health care cost, length of stay, and resource use up to 1 year after AVR, whereas patients with SVS had the lowest cost and resource use after AVR. The hospitalization costs for AVR were found to be the lowest at SVS for both TAVR and SAVR procedures. When comparing AVR hospitalization cost of SVS with those of PVS and AVS, higher absolute cost savings was observed for patients undergoing TAVR. These results underscore that the cost of AVR hospitalization is generally lower for TAVR compared with SAVR, and that significant cost savings can be achieved by intervening before the onset of symptoms. Recent evidence suggests that a strategy of early intervention (TAVR or SAVR) versus clinical surveillance is associated with improved outcomes for patients presenting with severe AS and no symptoms. 2 , 5 , 6 , 7 , 8 , 9 Our findings are consistent, suggesting that intervention while patients are still stable and asymptomatic may prevent the occurrence of AVS and preclude subsequent mortality, morbidity, and health care costs. The recent Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY&#8208;TAVR) trial demonstrated the superiority of early intervention with TAVR compared with clinical surveillance for patients with asymptomatic severe AS, a benefit that was mainly driven by unplanned cardiovascular hospitalization. Further assessment of patients randomized to clinical surveillance and eventually converted to AVR demonstrated that &#8776;40% of those patients experienced AVS before AVR, with severe symptoms such as NYHA III&#8211;IV, HFH, or syncope. Approximatively 60% of patients included in our study presented with AVS before AVR, which reflects the real&#8208;world nature of our study, with follow&#8208;up and clinical surveillance less optimal than the level performed in the randomized trial. Similarly, data from the Society of Thoracic Surgeons&#8211;American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC/TVT) demonstrated that up to 70% of patients undergo AVR while in NYHA class III&#8211;IV. 10 , 11 Given the detrimental impact on clinical and economic outcomes associated with undergoing AVR while presenting with AVS and PVS compared with SVS, a strategy of early intervention seems to be preferable among patients with severe asymptomatic AS. Presentation with AVS before AVR was associated with significantly higher costs during the index hospitalization ($101&#8201;150 AVS versus $88&#8201;065 SVS) and throughout the following year compared with patients with SVS. AVS was associated with stepwise increases in health care use, particularly for heart failure&#8208;related care, with patients with AVS experiencing nearly 5 times more HFH than patients with SVS. Similarly, AVS presentation was associated with a $36&#8201;000 increase in total cost during the first year post&#8208;AVR. These findings are important and suggest that early treatment could yield significant cost savings. These results complement previous studies examining the economic impact of delayed intervention in AS. Sethi et&#160;al found that delaying TAVR for a year was associated with an incremental cost of $9240 on average. 12 Chen et&#160;al demonstrated that acute HFH before AVR was associated with &#8776;30% higher costs, 13 whereas our more comprehensive clinical presentation assessment reveals even larger cost differentials when considering the full spectrum of disease progression. Similarly, our findings support Wald's observation that acute decompensation in AS leads to substantially higher resource use, 14 though we now demonstrate that&#160;this effect persists well beyond the initial hospitalization. Limitations Several limitations should be considered when interpreting our findings. First, the identification of asymptomatic patients through claims and EHR data presents inherent challenges because clinicians rarely document the absence of symptoms. This resulted in a relatively small asymptomatic cohort (n=270), leading to less precise estimates for this group compared with patients with PVS and AVS. Although our methodology for identifying truly asymptomatic patients is robust, the small sample size warrants cautious interpretation of the magnitude of differences among groups. The use of administrative claims, EHR data, and physician notes to classify disease severity has inherent limitations. Missing documentation, variability in coding practices, and inconsistent terminology in clinical notes may lead to misclassification of patients' clinical presentation. NLP of clinical notes, although advanced, may not capture all nuances of symptom description. Additionally, the temporal relationship between symptom onset and documentation may not always be precise in claims&#8208;based analyses. The Market Clarity database, although comprehensive, may not be fully representative of the broader AS population undergoing AVR. The database includes only patients from participating health care systems and insurers, potentially limiting generalizability. Socioeconomic and geographic factors influencing access to participating health care systems could introduce selection bias. Furthermore, variations in coding practices and documentation standards across health care systems may affect the consistency of our severity classifications. CONCLUSIONS AVS was the most frequent mode of presentation before AVR and was associated with increases in death, HFH, health care costs, and resource use 1 year after AVR compared with patients undergoing AVR while presenting with SVS. These findings extend beyond previous work by quantifying the substantial economic burden of delayed intervention and suggest potential cost savings of early intervention while patients are still stable and asymptomatic. Source of Funding None. Disclosures Dr G&#233;n&#233;reux is a consultant for Abbott Vascular; principal investigator of the Eclipse Trial (sponsored by Abbott Vascular); a consultant, advisor, and proctor for Edwards Lifesciences; the principal investigator for the EARLY&#8208;TAVR trial and Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS) trial (sponsored by Edwards Lifesciences); a consultant for egnite; a consultant for Medtronic; a consultant for and received equity from Pi&#8208;Cardia; a consultant for and received equity from Puzzle Medical; and a consultant for 4C Medical. Dr Baron received institutional research support from Acarix, received institutional research support from Abiomed, is a consultant for Boston Scientific, received institutional research support from Pi&#8208;Cardia (ShortCut trial), is on the advisory board and received speaking honoraria from Edwards Lifesciences, is on the advisory board and is a consultant and received speaking honoraria from Medtronic, is on the advisory board and received speaking honoraria from Zoll Medical, and received speaking honoraria and consultation fees from Shockwave Medical. A. Dratch, S. Murphy, and Dr Chikermane are employees of Edwards Lifesciences. The remaining authors have no disclosures to report. Supporting information Tables S1&#8211;S3 Data S1 References 1 Genereux P , Lindman BR , Pibarot P , Garcia S , Koulogiannis KP , Rodriguez E , Thourani VH , Giustino G , Sharma RP , Cohen DJ , et&#160;al. Acute valve syndrome in aortic stenosis . Structural Heart . 2024 ; 9 : 100377 . doi: 10.1016/j.shj.2024.100377 40321310 PMC12047511 2 Genereux P , Schwartz A , Oldemeyer JB , Pibarot P , Cohen DJ , Blanke P , Lindman BR , Babaliaros V , Fearon WF , Daniels DV , et&#160;al. Transcatheter aortic&#8208;valve replacement for asymptomatic severe aortic stenosis . N Engl J Med . 2024 ; 392 : 217 &#8211; 227 . doi: 10.1056/NEJMoa2405880 39466903 3 Elixhauser A , Steiner C , Harris DR , Coffey RM . Comorbidity measures for use with administrative data . Med Care . 1998 ; 36 : 8 &#8211; 27 . doi: 10.1097/00005650-199801000-00004 9431328 4 Gilbert T , Neuburger J , Kraindler J , Keeble E , Smith P , Ariti C , Arora S , Street A , Parker S , Roberts HC , et&#160;al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study . Lancet . 2018 ; 391 : 1775 &#8211; 1782 . doi: 10.1016/S0140-6736(18)30668-8 29706364 PMC5946808 5 Kang DH , Park SJ , Lee SA , Lee S , Kim DH , Kim HK , Yun SC , Hong GR , Song JM , Chung CH , et&#160;al. Early surgery or conservative Care for Asymptomatic Aortic Stenosis . N Engl J Med . 2020 ; 382 : 111 &#8211; 119 . doi: 10.1056/NEJMoa1912846 31733181 6 Banovic M , Putnik S , Da Costa BR , Penicka M , Deja MA , Kotrc M , Kockova R , Glaveckaite S , Gasparovic H , Pavlovic N , et&#160;al. Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long&#8208;term follow&#8208;up of the AVATAR trial . Eur Heart J . 2024 ; 45 : 4526 &#8211; 4535 . doi: 10.1093/eurheartj/ehae585 39217448 7 Loganath K , Craig NJ , Everett RJ , Bing R , Tsampasian V , Molek P , Botezatu S , Aslam S , Lewis S , Graham C , et&#160;al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial . JAMA . 2024 ; 333 : 213 &#8211; 221 . doi: 10.1001/jama.2024.22730 PMC11519785 39466640 8 Genereux P , Banovic M , Kang DH , Giustino G , Prendergast BD , Lindman BR , Newby DE , Pibarot P , Redfors B , Craig NJ , et&#160;al. Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: a systematic review and meta&#8208;analysis . J Am Coll Cardiol . 2024 ; 85 : 912 &#8211; 922 . doi: 10.1016/j.jacc.2024.11.006 39641732 9 Lindman BR , Braunwald E , Pellikka PA . Aortic valve replacement for asymptomatic severe aortic stenosis&#8208;the time has come . JAMA Cardiol . 2025 ; 10 : 305 &#8211; 306 . doi: 10.1001/jamacardio.2024.5648 39937467 10 Arnold SV , Manandhar P , Vemulapalli S , Kosinski AS , Batchelor WB , Thourani VH , Mack MJ , Cohen DJ . Trends in Transcatheter aortic valve replacement outcomes: insights from the STS/ACC TVT registry . JAMA Cardiol . 2024 ; 9 : 1115 &#8211; 1123 . doi: 10.1001/jamacardio.2024.3453 39412793 PMC11581560 11 Arnold SV , Manandhar P , Vemulapalli S , Vekstein AM , Kosinski AS , Spertus JA , Cohen DJ . Patient&#8208;reported vs. physician&#8208;estimated symptoms before and after transcatheter aortic valve replacement . Eur Heart J Qual Care Clini Outcomes . 2022 ; 8 : 161 &#8211; 168 . doi: 10.1093/ehjqcco/qcab078 34718485 12 Sethi A , Elmariah S , Gunnarsson C , Ryan M , Chikermane S , Thompson C , Russo M . The cost of waiting for a Transcatheter aortic valve replacement in Medicare beneficiaries with severe aortic stenosis . Structural Heart . 2024 ; 8 : 100321 . doi: 10.1016/j.shj.2024.100321 39670051 PMC11632791 13 Chen S , Redfors B , Crowley A , Ben&#8208;Yehuda O , Summers M , Hahn RT , Jaber WA , Pibarot P , Alu MC , Chau KH , et&#160;al. Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries . Eur J Heart Fail . 2020 ; 22 : 1866 &#8211; 1874 . doi: 10.1002/ejhf.1841 32441856 14 Wald DS , Williams S , Bangash F , Bestwick JP . Watchful waiting in aortic stenosis: the problem of acute decompensation . Am J Med . 2018 ; 131 : 173 &#8211; 177 . doi: 10.1016/j.amjmed.2017.08.027 28916422"
}